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ABSTRACT 
Secoisolariciresinol diglucoside (SDG) is the principal lignan of the flaxseed. In the 
human body it is metabolized to secoisolariciresinol (SECO) and then to enterodiol (ED) and 
enterolactone (EL). It has been shown that these compounds help to prevent the development of 
some hormone dependent diseases (breast, prostate cancers) and type II diabetes. Given 
numerous health benefits, evaluation of lignan pharmacokinetics is critical to understanding their 
pharmacology. This research aimed to assess SECO pharmacokinetic parameters in the rat.  
The first objective was to isolate pure SDG and SECO sufficient for a pharmacokinetic 
study. SDG (≥95% purity) was obtained from SDG (40% purity) by preparative HPLC. SECO 
(≥95% purity) was produced from SDG by acid hydrolysis. 
The second objective was to develop and validate an HPLC method with fluorescence 
detection suitable for pharmacokinetic applications. The method is specific for SECO, ED, and 
EL quantification in rat serum. Separation is achieved with a C18 reversed-phase column under 
gradient mobile phase conditions, consisting of water and acetonitrile buffered with 0.1% formic 
acid. Analytes are extracted with diethyl ether and 7-hydroxycoumarin serves as an internal 
standard. Calibration curves are linear from 0.01 to 10 µg/mL for SECO/ED and 0.05-10 µg/mL 
for EL. Accuracy and precision are within FDA specified limits. 
The third objective was to assess the pharmacokinetics of SECO after a single 
intravenous (20mg/kg) and oral bolus (40 mg/kg) administration in rat. SECO pharmacokinetic 
parameters were assessed based on a 12-hour study in Wistar male rats (n=12). The results were 
reported as mean ± SD: systemic clearance 3.1±1.0 L/h, volume of distribution 17.7±8.3 L, half-
life 4.7±3.6 h, and oral bioavailability 26 %. SECO undergoes enterohepatic recirculation and 
exhibits two-compartment model characteristics with large volume of distribution and low oral 
bioavailability. An additional 48-hour study indicated that SECO is present in systemic 
ii 
circulation at least for 21 hours after dosing. ED was detected and quantified in the 8-24 hours 
samples, while EL was detected in 15-36 hours samples after SECO administration.  
Additional pharmacokinetic studies with ED and EL are necessary to understand which 
lignan form may mediate the beneficial health effects. 
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1. INTRODUCTION 
Flaxseed is a major source of dietary intake of the lignan secoisolariciresinol diglucoside 
(SDG). Following oral consumption, SDG is converted to several metabolites: 
secoisolariciresinol (SECO), enterodiol (ED) and enterolactone (EL) (Section 2.2). Numerous 
animal and human studies indicate that flax lignans may be protective against breast, colorectal 
and prostate cancers (Section 2.3). It was also shown that consumption of SDG-rich flax extract 
could decrease elevated cholesterol and glucose in plasma, key components of cardiovascular 
health. Most of these studies are focused on EL and ED as bioactive molecules, although 
experimental design often involves consumption of ground flaxseed, flax flour, or SDG. 
Consequently, subjects are exposed to SECO as well (Section 2.3). Recent studies suggest that 
SECO is found in detectable quantities in plasma of many species, making it another potentially 
bioactive molecule. Moreover, Dr. Alcorn’s laboratory has established a hypercholesterolemic 
rat model and showed that chronic daily oral administration of SDG or SECO reduced total 
cholesterol within normal ranges in rats fed a high cholesterol diet1. Therefore, knowledge of 
SECO pharmacokinetics will help understand the pharmacology of lignans. 
Little information is available on SECO bioavailability and disposition (Section 2.4). The 
aim of my project is to enhance our understanding of SECO pharmacokinetics in the rat model. 
For this purpose, SECO pharmacokinetic parameters will be assessed after single intravenous 
and oral bolus administration in rats (Section 3.3). The pharmacokinetic study will also require 
isolation of pure SECO (Section 3.1) and development of a sensitive and simple method for 
lignan quantification in rat serum (Section 3.2). 
 
2. LITERATURE REVIEW 
2.1 Flaxseed, General Description and Composition 
Common flax or Linum usitatissimum is one of the oldest cultivated plants, with 
cultivation starting approximately 8,000 years ago in the region of Tigris and Euphrates rivers2. 
From ancient times it was used as a source of oil and fiber for weaving clothes. Today, long-stem 
varieties of flax are cultivated for linen production, while short-stem flax is cultivated for 
flaxseed oil, which is widely used in production of linoleum, stains, and paints3. In Canada, flax 
is one of the major crops, and Canada is the leader in oilseed flax production and export since 
19944. 
Flaxseed (oilseed variety) has about 40% lipids, 30% dietary fiber, 20% proteins, 4% ash, 
and 6% moisture (on whole seed basis)2,3. The lipid fraction of flaxseed consists of α-linolenic 
acid (ALA), linoleic, ricinoleic, and palmitic acids. ALA makes up to 55% of the total flax oil. 
Flaxseed has high content of polysaccharidic mucilage (6 to 8% by dry weight), which consists 
of acidic and neutral polysaccharides. A number of phytochemicals, such as lignans, cyanogenic 
glycosides, phenolic acids, isoprenoids, and flavonoids, are also present in flaxseed2. In addition 
to ALA, the lignans of flaxseed receive significant interest due to their putative health benefits in 
a number of chronic disease states. 
 
2.2 Lignans 
Lignans are a class of phytochemicals found in many plant species. Structurally lignans 
are dimeric compounds that consist of two phenlylpropanoid C6-C3 units coupled at the β and β’ 
carbon atoms5. In the plant the biological role of the lignans is still unclear, but it is assumed that 
they control the growth of the plant and provide protection from diseases and pests5,6. Lignans 
are found in all plant parts, including roots, flowers, fruit, seeds, and stems5,6. Biosynthesis of 
lignans is not yet understood, but they are presumed to be related to lignins5. According to recent 
findings, lignans are formed via dimerization of monolignols, allylphenols, or hydrocinnamic 
acids, depending upon the skeletal subclass formed3,5,7. 
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2.2.1 Flaxseed Lignans 
Flaxseed contains a number of lignans such as secoisolariciresinol diglucoside (SDG), 
secoisolariciresinol (SECO), isolariciresinol, pinoresinol, and matairesinol, which are 
concentrated in the outer layer of the seed and exist in the form of glucosides3,8. The main lignan 
of the flaxseed is SDG (9-30 mg/g of defatted flax meal), and flax is the richest source of SDG 
among foods (Figure 2.2.1)2. SDG is present in flax as a part of a soluble ester-linked complex 
that contains 3-hydroxy-3-methyl-glutaric acid (HMGA) and a number of cinnamic acid 
glucosides2,9. Recent studies by Struijs et al. showed that the lignan macromolecule consists of 
62% SDG, 5.7% herbacetin diglucoside (HDG), 12.2% p-coumaric acid glucoside (CouAG), 
11% HMGA, and 9% ferulic acid glucoside (FeAG) (w/w) (Figure 2.2.2). They also suggest that 
average lignan macromolecule has three backbone units (SDG or HDG) with a linker (HMGA) 
and terminal units (CouAG or FeAG)10,11. The chain length may vary from one to seven SDG 
moieties (Figure 2.2.3). 
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Figure 2.2.1 Chemical structures of secoisolariciresinol (SECO) and secoisolariciresinol 
diglucoside (SDG). 
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Figure 2.2.2 Chemical structures of the constituents of the flaxseed lignan macromolecule: 
HDG, CouAG, FeAG, and HMGA. 
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Figure 2.2.3 Schematic representation of the flaxseed lignan macromolecule suggested by 
Struijs et al11. The backbone units are SDG or HDG (1 out of 11units) coupled with linker 
HMGA through the ester bonds and CouAG , FeAG or HMGA as terminal units (n1+n2+n3≥1). 
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2.2.2 Mammalian lignans 
Mammalian lignans, or enterolignans, were identified independently by two groups of 
researchers during gas chromatographic –mass spectrometric analysis of urinary steroid extracts 
from human and animal species as glucuronic and sulfuric acids conjugates12-15. Enterolignans, 
enterodiol (ED) and enterolactone (EL), have also been found in human plasma, saliva, faeces, 
semen and prostatic fluids5. Axelson et al. established that enterolignans are formed by intestinal 
microflora from dietary sources rich in plant lignans, among which flaxseed had the highest 
lignan content16,17. From flaxseed, the main precursors of ED and EL are SDG, SECO, and 
matairesinol3. In vitro incubation with human fecal microflora showed that other plant lignans, 
lariciresinol, pinoresinol, syringaresinol, and 7-hydroxymatairesinol, could also be converted to 
ED and EL18. Figure 2.2.4 represents the chemical structures of ED and EL which, unlike lignans 
of plant origin, carry a hydroxyl group in the meta position rather than para position of aromatic 
ring13. Their identification following flaxseed consumption suggests a role for the enterolignans 
in the possible health benefits associated with flaxseed lignans. 
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Figure 2.2.4 Chemical structures of enterolactone (EL) and enterodiol (ED). 
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2.3 Health Benefits and Biological Activity 
Biological activity and potential health benefits of flaxseed lignans have been assessed in 
numerous in vitro and in vivo studies. Flaxseed lignans and their metabolites may be protective 
against some cancers (breast, endometrial, prostate, colorectal), and may reduce risk for 
cardiovascular disease, hyperlipidemia and type II diabetes19-22. 
 
2.3.1 Breast Cancer 
A series of studies on flaxseed, lignans, and breast cancer were conducted in Sprague 
Dawley female rats23-26. Animals were supplemented with flaxseed flour, defatted flaxseed meal, 
or SDG at 2.5%, 5%, or 10% levels for up to 22 weeks and different stages of mammary 
tumorigenesis were assessed. In the flaxseed group, 24 h after injection with carcinogen 
dimethylbenzanthracene (DMBA) cell proliferation was reduced by 38.8-55.4% and nuclear 
abberations were reduced by 58.8-65.9% in the female rat mammary gland23. Rats with 
established DMBA-induced tumors supplemented with flaxseed or SDG for 7 weeks had 50% 
reduction in tumor volume compared to control. A significant negative correlation was observed 
between excretion of lignans (ED and EL) in urine and tumor volume24. Similarly, flaxseed or 
SDG supplementation decreased invasiveness and grade of N-methyl-N-nitrosourea-induced 
mammary tumors in rats25. Additionally, reduced plasma levels of insulin-like growth factor-I 
(IGF-I), which is associated with increased breast cancer risk, were observed in rats 
supplemented with flaxseed or SDG26. Reduction of terminal end bud (TEB) structures (most 
susceptible to carcinogens) in rat mammary gland was observed after lifetime, gestation or 
lactation exposure to flaxseed or SDG, suggesting their protective role against mammary 
cancer27,28. Moreover, rats exposed to flaxseed or SDG during lactation had significantly lower 
tumor incidence, tumor load, and mean tumor size and tumor number induced by DMBA when 
compared to control29. An additional study showed that reduction of TEB structures occurs 
through epidermal growth factor receptor (EGFR) and estrogen receptor (ER) signaling30. 
Chen et al.31 assessed the role of flaxseed and SDG diets in mice with established estrogen-
negative human breast cancer tumors (MDA-MB-35). Mice supplemented with 10% flaxseed for 
15 weeks had significant reduction in tumor growth rate and 45% reduction in total incidence of 
metastasis compared to control group. Expression of IGF-I and epidermal growth factor receptor 
(EGFR) in the primary tumor were also significantly lower in the flaxseed group31. Moreover, a 
separate study with similar setup indicated that extracellular levels of vascular endothelial 
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growth factor (VEGF), key factor in promotion of tumor angiogenesis, were also significantly 
reduced32. Flaxseed (10%) and SDG (equivalent to 10% flaxseed) supplementation for 7 weeks 
reduced incidence of metastases in mice after excision of primary MDA-MB-35 tumor33. 
The effect of flaxseed supplementation was also studied in ovariectomized mice with 
established estrogen receptor-positive human breast cancer (MCF-7) tumors at low and high 
levels of circulating estrogens. Tumor size regressed by 74% after 6 weeks on 10% flaxseed diet 
at low estrogen levels. At high estrogen levels tumor growth was inhibited by 22% in the 
flaxseed group, and by 50% while in combination with tamoxifen (tamoxifen alone inhibited 
tumor growth only by 41%)34. An additional experiment confirmed that flaxseed diet does not 
stimulate tumor growth at low estrogen levels, while tamoxifen and soy protein do34-36. 
Moreover, analysis of tumor biomarkers in ovariectomized mice with established MCF-7 tumors 
at high levels of estrogen indicated that inhibition of tumor growth resulted from decreased cell 
proliferation and increased cell apoptosis in the flaxseed groups in a dose-dependent manner37. 
Expression of progesterone receptor (PgR) and IGF-I were also significantly reduced compared 
to control37. A recent study compared effects of flaxseed diet and equivalent supplementation of 
pure SDG in ovariectomized mice with established MCF-7 tumors with low estrogen levels38. 
Both treatments significantly inhibited cell proliferation and induced apoptosis, as well as 
significantly decreased mRNA expression of estrogen-responsive genes cyclin D1, pS2, ERα, 
ERβ, and biomarkers in growth factor-signaling pathways such as EGFR and IGF-I receptor, 
suggesting that SDG has similar effect as flaxseed in reducing tumor growth38. Saarinen et al. 
reported that SDG is also accessible to tumor tissues after oral administration of tritium labeled 
SDG to mice with established MCF-7 tumors39. 
The protective role of ED and EL against breast cancer was assessed in vitro in two 
estrogen receptor negative cell lines (MDA-MB-231 and MDA-MB-435). ED and EL inhibited 
steps involved in the metastatic cascade such as cell migration, invasion, and adhesion to 
Matrigel or extracellular matrices in a dose-dependent manner40. In MCF-7 estrogen receptor 
positive cell line ED and EL significantly inhibited aromatase and 17β-hydroxysteroid 
dehydrogenase (17β-HSD), with ED being more potent aromatase inhibitor, while EL being 17β-
HSD inhibitor41. Subcutaneous injections of ED or EL (10mg/kg) for 22 weeks in 
ovariectomized mice with established MCF-7 tumors with low estrogen levels did not promote 
tumor growth compared to negative control and significantly induced tumor cell apoptosis42. 
Ovariectomized mice with established MCF-7 tumors with high estrogen levels injected 
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subcutaneously with ED or EL (15 mg/kg) for 5 weeks showed decreased tumor growth and 
decreased extracellular levels of VEGF43. 
A number of case-control studies in humans examined association between serum EL and 
risk of breast cancer. An inverse association between serum EL and breast cancer risk was 
observed among premenopausal and postmenopausal women in Kuopio Breast Cancer Study, 
Finland44. Sonestedt et al. found that high plasma EL is associated with the reduced risk for ERα 
positive/ERβ negative breast tumors in nested case-control study in Sweden45. On the other hand, 
a prospective study in New York did not support protective role of EL46.  
Population-based studies on phytoestrogen dietary intake (isoflavones and lignans) and 
breast cancer in Ontario, Canada, indicate that lignan intake is associated with reduced breast 
cancer risk among overweight premenopausal women47. Additionally, adolescent lignan intake 
may be associated with decreased risk of adult breast cancer48. Furthermore, dietary lignan intake 
has been associated with improved survival among postmenopausal women with breast cancer in 
the Western New York Exposures and Breast Cancer Study49. 
 
2.3.2 Melanoma 
Two studies investigated the effect of flaxseed and SDG on the lung metastases of the 
murine melanoma B16BL6 cells in mice. Mice were supplemented with flaxseed or SDG at three 
concentration levels for two weeks before injection of B16BL6 cells and two weeks after the 
injection. The number of tumors in mice fed 2.5%, 5% and 10% flaxseed was 32%, 54% and 
63% lower than in control group50. Dietary supplementation of SDG also reduced the number of 
tumors in treated groups compared with the control, as well as decreased tumor cross-sectional 
area and tumor volume in a dose-dependent manner51.  
 
2.3.3 Endometrial Cancer and Uterine Fibroids 
A case-control study in the USA showed a negative association between dietary intake of 
lignans and endometrial cancer, which was statistically significant in postmenopausal women52. 
On the other hand, in the case-control study nested within three prospective studies in Sweden, 
Italy, and USA no correlation was found between serum EL levels and endometrial cancer53. 
Additionally, in a case-control study in the United States a modest inverse association was 
observed between lignan excretion and risk of uterine fibroids (hormonally responsive benign 
tumors)54.  
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2.3.4 Prostate Cancer and Benign Prostatic Hyperplasia 
Lin et al. investigated the effect of ED and EL on prostatic carcinoma in vitro55. Both 
lignans significantly inhibited the growth of three human prostate cancer cell lines (PC-3, DU-
145 and LNCaP), with EL being more potent inhibitor (IC50 = 57 µM for LNCaP cells) compared 
to ED (IC50 = 100 µM for LNCaP cells)55. The same research group studied the effect of 5% 
flaxseed diet on prostatic neoplasia in the transgenic adenocarcinoma mouse prostate model56. 
Mice supplemented with flaxseed for 30 weeks had significantly less aggressive tumors 
compared to control, reduced number of lung and lymph node metastases, significantly reduced 
cell proliferation and increased cell apoptosis56. Similar results were observed in rats with 
Dunning R3327 PAP prostate tumors supplemented with rye bran rich in lignans57. The number 
of palpable tumors and tumor volume were significantly lower in the rye bran group compared to 
control after 14 and 16 weeks of supplementation57. 
Human data on the role of lignans in prostate cancer are controversial. Stattin et al. found 
no association between serum EL and prostate cancer incidence in a nested case-control study 
conducted in Finland, Norway and Sweden58. However, men with very low plasma levels of EL 
had a significantly higher risk of prostate cancer59. In a case-control study on diet and prostate 
cancer in western New York a reduced risk of prostate cancer was observed in men consuming 
diet rich in lignans60. Another dietary study in Sweden found that intermediate levels of plasma 
EL were inversely associated with prostate cancer risk61. Furthermore, recent analysis of 
individual patient data from 12 prospective studies by Roddam et al. found an association 
between high circulating plasma IGF-I and prostate cancer risk62. SDG was shown to reduce 
IGF-I levels in rats and could be protective against prostate cancer26. 
Positive effect of lignans on benign prostatic hyperplasia was observed in a randomized 
double-blind placebo-controlled study in 87 subjects treated with SDG (300 or 600 mg/day) for 4 
months. After completion of the study the International Prostate Symptom Score decreased 
significantly, while Quality of Life improved compared to control group. Therapeutic efficacy of 
SDG was comparable with 5α-reductase inhibitors and α1A-adrenoreceptor blockers, commonly 
used for the treatment of benign prostatic hyperplasia63. 
 
2.3.5 Colorectal Cancer 
The protective role of flaxseed diet against colon cancer was observed in rats fed with 
flaxseed flour or flaxseed meal (5% or 10%) for 4 weeks following a single injection of 
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carcinogen azoxymethane. By the end of the experiment the total number of aberrant crypts and 
foci (early markers of cancer risk) was significantly reduced by 41-53% and 48-57%, 
respectively64. Additional study on long-term (100 days) exposure to flaxseed, defatted flaxseed 
or SDG in rats injected with azoxymethane had similar results, indicating that protective effect of 
flaxseed could be attributed to SDG65.  
EL and ED had an inhibitory effect on four colon cancer cell lines (LS174T, Caco-2, HCT-
15, T-84) in vitro, with EL being more effective than ED66. Moreover, EL suppressed growth of 
Colo 201 human colon cancer cells in vitro and in vivo (10 mg/kg EL injected subcutaneously to 
athymic mice with transplanted Colo201tumors for 18 days), by inducing apoptosis and 
decreasing cell proliferation67. Another study in multiple intestinal neoplasia mice, a model for 
colon tumorigenesis, did not show protective effect of 0.5% defatted flaxseed meal diet, although 
there was a tendency for decreased number of colon adenomas in the flaxseed group68.  
In a Dutch case-control study in humans, plasma levels of ED and EL were inversely 
associated with colorectal adenoma (colorectal cancer precursor) risk69. Another case-control 
study in Ontario, Canada, found that dietary lignan intake is significantly associated with 
reduced colorectal cancer risk70.  
 
2.3.6 Cardiovascular Health and Diabetes 
Cardioprotective role of flaxseed and lignans was assessed in a series of studies in 
hypercholesterolemic rabbits. Animals on atherogenic diet were supplemented with type II 
flaxseed low in α-linolenic acid for 8 weeks71. Type II flaxseed was chosen to evaluate effect of 
the lignan component of flax on development of atherosclerosis. The development of aortic 
atherosclerosis was reduced by 69% in the flaxseed group. Serum total cholesterol (TC) and low-
density lipoprotein cholesterol (LDL-C) were lower compared to control, while high-density 
lipoprotein cholesterol (HDL-C) was not affected71. Additional study with flaxseed oil suggested 
that the oil component of flax has no effect on serum lipids or extent of atherosclerosis in 
rabbits72. Furthermore, hypercholesterolemic rabbits supplemented for 2 months with SDG 
macromolecule complex (40 mg/kg per day) had decreased serum TC, LDL-C, and TC/HDL-C 
levels, while no changes were observed in normocholesterolemic rabbits73. Development of 
aortic atherosclerosis was reduced by 35%73. Protection against atherosclerosis was also 
observed in a study involving rabbits supplemented with an atherogenic diet for 4 months with 
SDG complex supplementation during the last 2 months of the experiment74. 
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Felmlee et al.1 observed a dose-dependent reduction in the rate of body-weight gain, serum 
TC and LDL-C, and hepatic lipid accumulation in hypercholesterolemic rats supplemented with 
equimolar quantities of SDG (3 or 6 mg/kg) and SECO (1.6 or 3.2 mg/kg) for 4 weeks1. Another 
study in rats fed high cholesterol diet for 8 weeks followed by oral administration of SDG (20 
mg/kg) for 2 weeks showed a significant reduction in TC, LDL-C, triglycerides and increase in 
HDL-C levels, compared to control75. Protective effect of SDG against ischemia-reperfusion 
injury ex vivo was also observed in the same study, as well as significant improvement in left 
ventrical functions in induced myocardial infarction in vivo75. 
Prasad et al.76,77 assessed the protective role of SDG against type II diabetes in rats. 
Incidence of streptozotocin-induced diabetes in rats supplemented with 22 mg/kg SDG for 21 
days was reduced by 75%76. In Zucker diabetic fatty rats (model for type II diabetes) treated with 
SDG (40 mg/kg orally) starting at age 6 weeks, development of diabetes was delayed in 80% of 
animals in the treatment group77. 
Recent studies showed beneficial effect of SDG on hypercholesterolemia and 
hyperglycemia in humans. In a randomized double-blind placebo-controlled study 55 
hypercholesterolemic subjects were given SDG (300 and 600 mg/day) for 8 weeks. By the end of 
experiment SDG significantly reduced plasma TC, LDL-C, and fasting glucose levels in a dose-
dependent manner78. Another randomized double-blind placebo-controlled study in 72 diabetic 
patients with mild hypercholesterolemia given 360 mg/ day of SDG for 12 weeks suggested that 
SDG modulates levels of C-reactive protein, a marker for chronic inflammation and one of the 
key factors in pathogenesis of type II diabetes79.  
Vanharanta et al. reported that high serum EL levels were associated with reduced 
coronary heart disease-related and cardiovascular disease-related mortality in middle-aged 
Finnish men in Kuopio Ischaemic Heart Disease risk factor study80. On the other hand, Kuijsten 
et al. did not associate high plasma ED and EL with a reduced risk on nonfatal myocardial 
infarction in prospective case-control study in Netherlands81. Peterson et al. in their recent 
review of the epidemiological studies on lignan dietary intake suggested that lignans might be 
protective against cardiovascular disease, although more research is needed22. 
 
11 
2.4 Pharmacokinetics of Flaxseed Lignans 
An understanding of lignan pharmacokinetics (PK) is critical for assessments of 
biological activity, mechanism of action and potential therapeutic application (i.e. size and 
frequency of dose, therapeutic concentration). To date, limited PK data exists for the flaxseed 
lignans. For a long time only EL was in the scope of interest of researchers. Information on 
lignan bioavailability and serum and tissue levels of the various lignan forms and their oxidative 
or phase II metabolites is limited. Available evidence suggests lignans undergo extensive 
enterohepatic recirculation such that the liver and gastrointestinal tract are exposed to high levels 
of the lignans. 
 
2.4.1 Absorption and Gastrointestinal Metabolism 
Shortly after discovery of mammalian lignans studies in rats and humans confirmed that 
ED and EL were produced by intestinal microflora and were metabolites of SDG from flaxseed 
(mammalian lignans were not detected in germ-free rats)16,17. A simplified scheme for the 
conversion of SDG into ED and EL was first proposed by Axelson et al. in 198217, and was 
clarified in recent studies (Figure 2.4.1)82-88. 
To date, research indicates that following flaxseed consumption the lignan 
macromolecule breaks down to SDG and various combinations of SDG and HMGA in the acidic 
environment of stomach and SDG is completely released from macromolecule in the small 
intestine85. Milling and crushing of flaxseed was shown to improve the conversion to 
enterolignans89. The glucose groups on SDG are then hydrolyzed by microbial and intestinal 
brush border β-glucuronidase or β-glucosidase to produce the aglycone SECO82,90. Bacteroides 
and Clostridium species are responsible for deglycosylation of SDG in humans87,91. Glitso et al. 
suggested the conversion occurs between terminal ileum and caecum in pigs92. Similarly, 
Eeckhaut et al. observed SDG conversion into SECO in the ascending colon compartment in the 
human artificial digestion model, which is supported by an earlier study in patients with 
ileostomies having low plasma lignan levels85,93. Then, SECO is partially absorbed into systemic 
circulation as was shown in a recent study by Laerke et al.94 or is converted to mammalian 
lignans by gut microflora86-88. In vitro and in vivo studies showed that SECO is first 
demethylated by Blautia producta and Eubacterium limosum, and then dehydroxylated by 
Eggertella lenta to produce ED82,83,86,88,91. ED is dehydrogenated to EL by recently isolated 
Lactonifactor longoviformis87,88. 
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Figure 2.4.1 Proposed metabolic pathway for the conversion of SDG by intestinal microflora 
(adopted from Wang et al.82). 
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Intestinal lignan metabolism varies significantly among the population, which can be 
stratified into high, moderate and low ED/EL producers84. Additionally, in vitro SECO 
incubation with human fecal samples showed that high concentration of Blautia producta and 
bacteria belonging to Atopobium group was typical for high EL-producers, while ED production 
was negatively correlated with abundance of Clostridium coccoides-Eubacterium rectale 
cluster83,84.   
 
2.4.2 Phase I and Phase II Metabolism 
Once absorbed from the intestine, SECO, ED and EL undergo conjugation reactions with 
glucuronic and sulfuric acids by phase II enzymes. Analysis of urine and plasma in humans 
suggested that lignans form mainly glucuronides (up to 98%) and smaller quantities of 
monosulfates and disulfates15,95,96. Similar results were obtained in vitro, after EL was incubated 
with human and rhesus monkey hepatocytes with reaction catalyzed by human UGT1A and 
UGT2B family members97. Study in rats also showed that conjugates are excreted into bile and 
undergo enterohepatic circulation16. Another study with human colon epithelial cell lines (CaCo-
2 and HT29) suggested that ED and EL could be also conjugated during the uptake in the colon, 
with EL being more rapidly metabolized than ED98. 
SECO, ED and EL are as well substrates for cytochrome P-450-mediated hydroxylation 
reactions. In vitro studies on lignan oxidative metabolism in human, pig, rhesus monkey, and rat 
microsomes gave a number of aromatic and aliphatic monohydroxylated derivatives97,99-101. 
Similarly, a number of aromatic and aliphatic hydroxylated metabolites were detected in bile and 
urine of rats dosed, either orally or intraduodenally, with ED and EL (10 mg/kg)102. Interestingly, 
SECO incubated with human and rat liver microsomes could be metabolized into lariciresinol 
and isolariciresinol101. Nine aromatic metabolites of ED and EL were also identified in urine of 
humans supplemented with flaxseed for 5 days, although they accounted for less than 5% of the 
total urinary lignans103. A recent study in human and rhesus monkey hepatocytes also indicates 
that hydroxylation is a minor metabolic pathway for lignans97. 
 
2.4.3 Distribution 
Analysis of lignan levels in serum shows a wide range of concentrations within 
population. Adlercreutz et al.95 reported higher levels of ED and EL in vegetarian women (ED 
1.1-140.3 nmol/L; EL 17.9-1078.2 nmol/L) than in omnivorous women (ED 0-5.6 nmol/L; El 
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10.4-74.1 nmol/L)95. Kilkkinen et al.104 found wide variation in serum EL levels in 2380 Finnish 
adults (men: 0-95.6 nmol/L; women: 0-182.6 nmol/L)104. ED and EL have been also quantified 
in human saliva, prostatic fluid, and semen5,105. Furthermore, study in 7 healthy Japanese women 
at delivery suggests that lignans freely pass the placental barrier, as maternal plasma ED and EL 
concentrations significantly correlated with levels in cord plasma and amniotic fluid106.  
Rickard and Thompson assessed tissue lignan distribution in rats over 48 hours after 
acute and chronic (rats gavaged with 1.5 mg/day of SDG for 10 days) tritium labeled SDG (3H-
SDG) treatment107. Total lignans were measured as radioactivity by liquid scintillation in16 
tissues, as well as blood, urine and faeces. More than 80 % of recovered dose was excreted by 48 
hours. Caecum had the highest lignan level throughout the experiment. Other tissues with high 
lignan concentrations were liver, kidney and uterus. Chronic exposure to SDG resulted in 
delayed fecal excretion of lignans while increasing levels in liver and adipose tissue, suggesting 
lignan accumulation in tissues107. Similarly, Murray et al.108 observed dose-dependent 
accumulation of ED and EL in liver, testes, lungs, and prostate in male rats supplemented with 
linola meal for 7 days108. A recent study on lignan tissue distribution in adult male and female 
rats supported earlier results and also suggested sex-related differences in lignan distribution 
(female rats had higher lignan concentrations in heart and thymus)109. In another study in pigs 
fed rye bread diet rich in lignans for 58-67 days significant EL concentrations were found in the 
colon (691.7±93.63 pmol/g), liver (125.0±19.63 pmol/g), and breast tissue (25.8±4.12 pmol/g). 
EL was also found in brain tissue (2.3±0.41 pmol/g)94. In the same study bile analysis showed 
domination of plant lignans (77%: SECO, matairesinol, and lariciresinol) as opposed to EL 
(23%), with 6.2±0.9 µmol/L of total lignans94. One study in rats gavaged with 3H-SDG also 
suggested that lignans could be transferred via dam’s milk to the offspring, although lignan form 
was not specified110. 
 
2.4.4 Excretion 
Conjugated lignans are excreted through the urinary and biliary systems16. Human dietary 
studies suggest a dose-dependent increase in ED and EL urinary excretion following increasing 
flaxseed consumption111,112. Following SDG consumption in 12 volunteers 40 % of the ingested 
dose was excreted within 3 days with the majority as EL113. Similar results were obtained in rats 
gavaged with 3H-SDG where 28-32% of recovered dose was excreted in urine within 48 
hours107. Total lignan excretion (measured as radioactivity by liquid scintillation) increases 
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significantly after prolonged exposure to SDG109. In another study in rats given SECO (25 
mg/kg), ED and EL were the main urinary metabolites with smaller quantities of SECO and 
traces of lariciresinol and isolariciresinol114. 
Lignan urinary excretion varies significantly within population. Analysis of urine 
samples of women on habitual diet suggests that urinary EL excretion is the highest (1691 
ng/mL), followed by ED (234 ng/mL) and SECO (124 ng/mL), although the range of 
concentrations is wide (EL: 2-13156 ng/mL; ED: 0-4337 ng/mL; SECO: 0.7-3200 ng/mL)115. 
The early studies by Axelson and Setchell showed that lignans are excreted into human 
and rat urine mainly as glucuronides (98% for EL and 92% for ED of total lignans), sulfates (2% 
for EL and 7% for ED of total lignans), and small amounts of disulfates15,16. Adlercreutz et al.96 
also reported a sulfoglucuronide fraction of ED, EL and matairesinol in human urine96. With 
more advanced methods for lignan analysis small quantities of conjugated SECO, isolariciresinol 
and lariciresinol were found in urine samples of women on habitual diet116, as well as 
syringaresinol and pinoresinol117.  
Little information is available on lignan biliary excretion. In study by Axelson and 
Setchell rats excreted relatively high amounts of ED (0.4 µg/24h) and EL (14 µg/24h) into bile in 
the form of glucuronides (up to 99% of total enterolignans)16. Traces of mono- and disulfates 
were also detected. In another study in pigs fed a rye diet, plant lignans accounted for 77% of the 
total lignans (SECO: 13%), while ED and EL accounted only for 23% of total lignans (6.2±0.9 
µmol/L)94.  
After biliary excretion into the duodenum, lignans undergo deconjugation with bacterial 
β-glucuronidase. Unconjugated lignans could be reabsorbed or be excreted into faeces. As with 
bile, little is known about fecal excretion of lignans. In rats gavaged with 3H-SDG, 40% to 83% 
of the administered dose is excreted into faeces109. In humans, EL and ED are two major lignans 
found in faeces118. Small quantities of matairesinol were also detected in women on habitual 
diet118. Similar to urinary excretion, flaxseed supplementation caused increased fecal excretion 
of EL and ED (16- to 32-fold) in women119. The slight increase in matairesinol excretion (1.6-
fold) was also observed in the same study, suggesting SECO could also be eliminated via faeces. 
Unfortunately, SECO analysis was not performed at that time119. 
 
2.4.5 Pharmacokinetic (PK) parameters 
Several studies attempted to assess PK parameters of lignans in humans113,120,121. Due to 
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high cost and complexity of obtaining pure lignans in quantities sufficient for conducting the 
experiment, only one study was done with pure SDG, while the others used sesame seeds and 
strawberries.  
Mazur et al.120 measured EL plasma levels and urinary excretion in 7 volunteers after the 
consumption of a single dose of strawberries (500 g) equivalent to 11.7 mg of SECO and 0.61 
mg of matairesinol120. EL appeared in plasma 8 hours after the strawberry meal, reaching 
maximum at 24 hours. Maximum EL excretion was observed in 25-36 hour urine samples.  
Similarly, in 12 volunteers EL and ED appeared in plasma 8-10 hours after the ingestion 
of a single dose of purified SDG (1.31µmol/kg body weight)113. ED maximum plasma 
concentration was observed 14.8±5.1 hours, while EL maximum was reached 19.7±6.2 hours 
post dose. Elimination half-life was 4.4±1.3 h for ED and 12.6±5.6 h for EL. The mean residence 
time for ED was 20.6±5.9 h and 35.8±10.6 h for EL. 
Penalvo et al.121 calculated PK parameters for several plant lignans in 4 volunteers after 
the consumption of a single dose of sesame seeds (50g) equivalent to 186.5 mg of total lignans 
including 7.4 µg of SECO121. Taking into consideration that SECO is a minor constituent of 
sesame seeds, researchers were able to calculate only absorption half-life (1.45±0.59 h) and time 
needed to maximum plasma concentration (6.25±2.25 h).The sampling schedule was not 
appropriate for determination of PK parameters for ED and EL. Similar to other studies, their 
concentration increased during the period 10-24 h after the ingested dose121. 
 
2.5 Analytical Methods for Lignan Quantification in Biological Fluids 
Analytical methods for lignan determination and quantification reported in the literature 
usually involve mass spectrometry (MS) or tandem mass spectrometry (MS/MS) coupled with 
gas or liquid chromatography3,5,6,122,123. Procedures vary depending on the nature of analyzed 
sample. Based on the reviewed studies, quantification of ED and EL in biological fluids, as 
molecules potentially responsible for observed health benefits, was the main focus of researchers 
over the years. At the same time, methods for SDG and SECO quantification were developed 
mainly for analysis of flaxseed and food samples. 
 
2.5.1 Gas Chromatography 
The development of lignan analysis in biological fluids started from gas 
chromatographic-mass spectrometric (GC-MS) urine analysis of steroid compounds13. ED and 
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EL were among first lignans identified and quantified using capillary gas chromatography (GC) 
with flame ionization detector and GC-MS in urine samples of humans and several animal 
species13,15,124, and later in rat bile and plasma16. Both forms of lignans, unconjugated and 
conjugated (glucuronides, mono- and disulfates) were analyzed. Sample preparation involved 
prior separation of conjugated and unconjugated compounds on ion exchange column followed 
by conversion to trimethylsilyl (TMS) ether derivatives and GC or GC-MS analysis with 3α-
hydroxy-5β-cholestane as internal standard. Lignan conjugates were hydrolyzed enzymatically 
(β-glucoronidase for glucuronides) or treated with acidified tetrahydrofuran (for sulfates) before 
reaction with silanization agents. The method was then adapted by Bannwart C. et al. for 
detection and quantification of SECO in human urine116.  
Setchell et al. also proposed quantification of ED and EL in urine and serum using stable 
isotope dilution GC-MS in the selected ion monitoring mode125. The method involved hydrolysis 
with β-glucoronidase from Helix Pomatia multiple steps extraction procedure using liquid-solid 
extraction and ion-exchange chromatography and addition of deuterium-labeled standards ([D2]-
EL and [D2]-ED). A similar method was reported by Adlercreutz et al. for quantification of ED, 
EL118, as well as isoflavonoids in human urine, where [D6]-EL and [D6]-ED were used as 
standards. The method was then modified for analysis of plasma95 and faeces126 in man, and 
recently SECO127 was included into analysis.  
Grace et al.128 proposed an assay for ED and EL in low volumes of urine (200µL) by GC-
MS in selected ion monitoring mode using 13C3-labeled standards. Sample preparation requires 
reaction of deconjugation with β-glucoronidase/sulfatase, followed by one-step solid-phase 
extraction (SPE), and silanization of unconjugated ED and EL128. Sensitivity of the method is 
reported to be 1.2 ng/mL for ED and 5.3 ng/mL for EL. 
 
2.5.2 Liquid Chromatography 
Taking into consideration that GC methods for lignan analysis require laborious and time 
consuming clean-up procedure, and derivatization of analytes to make them volatile, a number of 
methods using high performance liquid chromatography (HPLC) were also developed.  
An HPLC method with coulometric electrode array detection was reported for monitoring 
of phytoestrogens in plasma and urine, including SECO, ED, and EL129,117. Sodium acetate 
buffer-methanol-acetonitrile mixture was used as an eluent. Sample preparation included 
glucuronidase pretreatment and double extraction with diethyl ether. Run time was 85 min. The 
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method was later optimized for quantification of 11 lignans in human plasma, with run time 
reduced to 50 min and limit of detection (LOD) SECO 1.36 nmol/L, ED 0.85 nmol/L, and EL 
1.55 nmol/L, but plasma sample needed additional clean-up using ion-exchange 
chromatography130. 
Several sensitive and selective methods using HPLC coupled with tandem mass 
spectrometry were published recently. An HPLC-MS/MS method with heated nebulizer 
atmospheric pressure chemical ionization (HN-APCI) was developed for the determination of 
phytoestrogens, including ED and EL, in human serum and urine. Sample preparation includes 
pretreatment with β-glucuronidase/sulfatase, SPE, and addition of deuterium-labeled analytes as 
internal standards (LOD 0.1-1.1 ng/mL for serum and 0.5-3.3 ng/mL for urine)131. Another 
highly sensitive (LOD 10 pg/mL) HPLC-MS/MS method using triple quadrupole mass 
spectrometer in negative ion electrospray mode was reported for quantification of isoflavones, 
ED and EL, and later SECO, in human serum and urine using triply C13-labeled standards132,115. 
Sample preparation also requires prior deconjugation with β-glucuronidase and SPE. The method 
was later optimized by Kuijsten et al. for the measurement of ED and EL only in human plasma, 
by reducing time needed for reaction of deconjugation from 12 to 4 hours133. 
 
2.5.3 Time-Resolved Fluoroimmunoassay 
A time-resolved fluoroimmunoassay (TRF) was developed for screening of the large 
number of samples, necessary in epidemiological studies. An assay was developed only for EL 
quantification in plasma and urine134-136. Briefly, conjugated EL is enzymatically hydrolyzed by 
β-glucoronidase/sulfatase, EL is extracted and then incubated with specific rabbit antibody and 
europium-labeled EL derivative, where analyte and labeled compound are competing for binding 
with antibody. After the bioaffinity reaction is completed, europium is dissociated from the 
antibody-EL derivative complex and its fluorescence is measured at a fixed time after the 
excitation of fluorophore. The method is sensitive (1.5 nmol/L), specific, though there is some 
cross-reactivity with ED, and allows the processing of high number of samples134. 
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2.6 Methods of Lignan Analysis in Flax and Food samples 
An increasing interest in mammalian lignans, ED and EL, and their biological role led to 
the development of methods for quantitative analysis of SDG and SECO in food, suitable to 
conduct dietary intake studies (since SDG and SECO were found to be the main precursors of 
ED and EL). Most of the reported methods for lignan quantification in flax and food samples use 
different types of hydrolysis reactions to convert lignans from glycoside to aglycone form with 
subsequent analysis of aglycones using GS-MS or HPLC-MS.  
In 1991 Thompson et al.137 adapted capillary GC-MS method reported by Fotsis et al.124 
to measure ED and EL that could be produced from various foods137. Food samples were 
fermented in vitro by human colonic microflora prior to analysis.  
In 1995 Obermeyer et al.138 quantified SECO in flax and flax meal using HPLC with UV 
detection at 280 nm and coumarin as internal standard. Samples were hydrolyzed with β-
glucuronidase, rinsed with acetonitrile, and subjected to SPE before HPLC analysis138. 
In 1996 Mazur et al.139 proposed acid hydrolysis for analysis of SECO and matairesinol 
in flax and selected foods along with simultaneous quantification of several isoflavonoids by 
isotope dilution GC-MS139. Sample preparation involved enzymatic hydrolysis and ether 
extraction of isoflavonoids followed by acid hydrolysis with hydrochloric acid (HCl) for 2.5 
hours and ether extraction of lignan aglycones. Then ether fractions were purified by ion-
exchange chromatography, silylated and analyzed using GC-MS. Deuterated analytes were used 
as internal standards. Sensitivity of the method was reported to be 2-3 µg/100g of the sample. 
Later Liggins et al.140 modified the method for quantification of SECO, shonanin and 
matairesinol. Sample preparation included acid hydrolysis with HCl for up to 3 hours, triple 
extraction of lignan aglycones with ethyl acetate and methyl tert-butyl ether mixture, followed 
by silanization and GC-MS analysis. Anthraflavic acid was used as internal standard140. 
Researchers reported more than 4-times higher levels of SECO in flaxseed, than those obtained 
by Obermeyer et al.138, since β-glucuronidase did not completely hydrolyze lignan glycosides as 
opposed to hydrochloric acid. The drawbacks of the method included formation of the artifacts 
during acid hydrolysis, when SECO is dehydrated to anhydrosecoisolariciresinol (ASECO) 
which is structurally similar to the naturally occurring lignan shonanin. Therefore, lignan levels 
could only be reported as the total concentration of SECO and shonanin. Also optimal time for 
acid hydrolysis varied depending on a food matrix140. 
Considering instability of lignans during acid hydrolysis, Milder et al.141 combined 
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enzyme and alkaline hydrolysis to quantify SECO, lariciresinol, matairesinol, and pinoresinol in 
foods using liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) with 
atmospheric pressure chemical ionization (APCI). Samples were treated with 0.3M sodium 
hydroxide (NaOH) at 60°C for 1 h, followed by overnight hydrolysis with β-glucuronidase, and 
extracted twice with diethyl ether before analysis. Deuterated SECO and matairesinol were used 
as standards. Sensitivity of the method was reported to be 4-10 µg/100 g of sample141. Alkaline 
hydrolysis of the sample improved lignan yield by 80% compared to enzymatic hydrolysis alone. 
Later Penalvo et al.142 adapted sample pretreatment procedure used by Milder et al.141 for 
quantification of SECO, matairesinol, lariciresinol, pinoresinol, medioresinol, and syringaresinol  
by isotope dilution GC-MS in food items.  13C3-labeled lignans were used as internal standards 
and sensitivity of the method was reported to be 6-12 µg/100 g of sample. 
Several methods for SDG quantification have been reported over the years. Muir and 
Westcott143 suggested HPLC method with UV detection at 280 nm after base hydrolysis of flax 
and flax containing food items. Samples were defatted by hexane and subjected to alkaline 
hydrolysis with 0.5 N NaOH for 3 hours before HPLC analysis. SDG was separated using 1% 
acetic acid and methanol as mobile phase, with gradient applied, and 60 min runtime. Similarly, 
Johnsson et al.144 reported HPLC method with UV detection at 280 nm for SDG analysis in 
defatted flaxseed flour. Sample was extracted with 1,4-dioxane-methanol mixture, hydrolyzed 
with 0.3 M NaOH for 48 hours, and purified by SPE. Runtime was reduced to 32 min with 5% 
acetonitrile in 0.01M phosphate buffer and acetonitrile as mobile phase. 
 
2.7 Purpose and Objectives 
2.7.1 Purpose 
Lignans are reported to have numerous health benefits. For many years enterolignans, 
and especially EL, were in the scope of researchers’ interest as possessing those benefits. 
Consequently, analytical methods for lignan quantification in biological fluids were developed 
firstly for enterolignans. SDG and SECO were viewed as precursors of ED and EL, and were 
analyzed mostly in various foods to assess dietary lignan intake. Recent studies suggest that 
SECO is found in detectable quantities in plasma of many species. Furthermore, many studies on 
biological activity of lignans were conducted using flaxseed, due to the expensive and labourious 
procedure of obtaining pure substances in quantities sufficient for experiment. That means, study 
participants were exposed to SDG, SECO, ED, and EL, leaving unanswered the question of 
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which molecule is biologically active. Consequently, knowledge of SECO pharmacokinetics is 
critical for understanding the pharmacology of lignans. 
Few studies have assessed the pharmacokinetics of lignans and those conducted provide 
an incomplete overview of lignan bioavailability and disposition. My laboratory has established 
a hypercholesterolemic rat model and showed that chronic daily oral administration of SDG or 
SECO reduced total cholesterol and LDL-cholesterol within normal ranges in rats fed a high 
cholesterol diet. To understand the underlying mechanism of lignan action in this model system 
requires a complete understanding of lignan pharmacokinetics. Therefore, the purpose of my 
M.Sc. project was to conduct a pharmacokinetic analysis of SECO in the rat to enhance our 
understanding of flaxseed lignan absorption and disposition characteristics. The aims of this 
project were accomplished by the following objectives: 
 
2.7.2 Objective 1 
 Isolate and purify secoisolariciresinol diglucoside and secoisolariciresinol from 40% 
lignan starting material. 
 
2.7.3 Objective 2 
 Develop and validate an HPLC method with fluorescence detection for quantification of 
secoisolariciresinol, enterodiol and enterolactone in rat serum. 
 
2.7.4 Objective 3 
Assess the pharmacokinetics of secoisolariciresinol after single intravenous and oral 
bolus administration in rat. 
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3. MATERIALS AND METHODS 
3.1 Isolation of SDG and SECO From 40% Flaxseed Lignan Starting Material 
3.1.1 Chemicals 
SDG (40% purity) starting material, SECO (≥99% purity), SDG (≥99% purity) were 
kindly provided by Dr. Muir’s lab, Agriculture and Agri-Food Canada Saskatoon Research 
Center, SK. Water (Optima LC/MS grade), acetonitrile (Optima LC/MS grade), methanol 
(HPLC grade), glacial acetic acid (certified ACS grade), hydrochloric acid (HCl, certified ACS 
grade), formic acid (Optima LC/MS grade), sodium hydroxide (NaOH, 40% analytical grade) 
were purchased from Fisher Scientific Company (Ottawa, ON, Canada). Water for preparative 
chromatography was purified using a Millipore super Q water system (Millipore, Bedford, MA, 
USA). 
 
3.1.2 Preparative High Performance Liquid Chromatography (HPLC) 
SDG and SECO purification was performed using a Waters PrepLC 4000 system (Waters 
Corporation, Milford, MA, USA) which included a 486 Tunable Absorbance Detector set at 
280nm, PrepLC controller with pumps, and PrepLC Universal Base with 3 (40 ×100 mm Waters 
C18 Bondapak 15-20 μm, 125Ǻ packing) cartridges and 1 (40 ×100 mm Waters C18 Bondapak) 
guard insert. SDG and SECO were separated under several gradients (Tables 3.1.1-3.1.3) at flow 
rate of 50 mL/min. Mobile phase consisted of 1% acetic acid or 2% acetic acid in Millipore 
water and methanol. At 0.05 min into the gradient, the starting material (SDG 40%; SECO 40%, 
or SECO 75%) in an 80:20 water:methanol mixture was introduced into the preparative HPLC 
system (Table 3.1, 3.2, and 3.3 respectively). 
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 Table 3.1.1 Preparative HPLC mobile phase linear gradient 
conditions for secoisolariciresinol diglucoside (SDG) purification 
 
Time 
(min) 
1% Acetic acid in 
Millipore water (%) 
Methanol  
(%) 
0 
0.05 
0.55 
8 
25 
80 
90 
120 
95 
- 
95 
90 
60 
10 
95 
95 
5 
- 
5 
10 
40 
90 
5 
5 
 
 
Table 3.1.2 Preparative HPLC mobile phase linear gradient 
conditions for secoisolariciresinol (SECO) (40%) purification 
 
Time  
(min) 
2% Acetic acid in 
Millipore water (%) 
Methanol  
(%) 
0 95 5 
0.05 - - 
0.55 95 5 
5 95 5 
20 80 20 
55 70 30 
75 5 95 
80 5 95 
90 95 5 
120 95 5 
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Table 3.1.3 Preparative HPLC mobile phase linear gradient 
conditions for secoisolariciresinol (SECO) (75%) purification  
 
Time  
(min) 
2% Acetic acid in 
Millipore water (%) 
Methanol  
(%) 
0 80 20 
0.05 - - 
0.55 80 20 
15 80 20 
55 50 50 
75 5 95 
85 5 95 
95 95 5 
120 95 5 
 
 
3.1.3 Analytical Ultra Performance Liquid Chromatography (UPLC) 
SDG and SECO content in fractions collected during preparative HPLC or during the 
acid hydrolysis (see section 3.1.6) was controlled using a Waters Acquity UPLC System (Waters 
Corporation, Milford, MA, USA). SDG and SECO were separated on an Acquity UPLC BEH 
C18 column (2.1×50 mm, 1.7 μm particle size, Waters Corporation, Milford, MA, USA) using 
several gradients (Tables 3.1.4-3.1.5). Mobile phase consisted of 1% formic acid in water and 
acetonitrile. Injection volume was 15 μL. Analyte peaks were detected at 280 nm using an 
Acquity Photodiode Array (PDA) detector (Waters Corporation, Milford, MA, USA). 
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 Table 3.1.4 UPLC mobile phase linear gradient conditions for control of secoisolariciresinol 
diglucoside (SDG) content in fractions collected 
 
Time 
(min) 
Flow rate 
 (mL/min) 
1% Formic acid in Optima 
water (%) 
Acetonitrile 
(%) 
0 0.8 95 5 
0.25 0.8 95 5 
0.6 0.8 80 20 
1.95 0.8 30 70 
2.25 0.8 95 5 
4.25 0.8 95 5 
 
 
 
 
Table 3.1.5 UPLC mobile phase linear gradient conditions for control of secoisolariciresinol 
(SECO) content 
 
Time 
(min) 
Flow rate 
(mL/min) 
1% Formic acid in Optima water 
(%) 
Acetonitrile 
(%) 
0 0.6 95 5 
2.5 0.6 50 50 
2.61 0.6 95 5 
3.25 0.6 95 5 
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3.1.4 Ultra Performance Liquid Chromatography/Mass Spectrometry (UPLC/MS) 
SDG and SECO identity was confirmed by mass spectrometry using a Synapt HDMS 
System (Waters Corporation, Milford, MA, USA) with Synapt Q-TOF analyzer at negative ES 
ionization mode and Waters Acquity UPLC System with Waters Acquity PDA detector set at 
280 nm. UPLC analysis was performed using the mobile phase gradient indicated in Table 3.1.4 
with 1% formic acid in water and acetonitrile as mobile phase on an Acquity UPLC BEH C18 
column (2.1 50 mm, 1.7 μm particle size, Waters Corporation, Milford, MA, USA). ×
 
3.1.5 Secoisolariciresinol Diglucoside (SDG) Purification 
Starting material (SDG content 40%) was dissolved in water-methanol (80:20) mixture 
and injected onto the preparative column (Table 3.1.1). Time intervals for fraction collection 
were set in accordance with time of SDG peak elution. Fractions were analyzed for SDG content 
using UPLC (Table 3.1.4), evaporated to dryness in rotary evaporator (RE-121, Buchi 
Laboratoriums-Technik AG, Switzerland), dissolved in Millipore water, and freeze-dried 
(FreeZone Freeze Dryer, Labconco Co., Kansas City, MO, USA). Lyophilisates with SDG 
content less than 80% were subjected to further purification.  
 
3.1.6 Secoisolariciresinol (SECO) Production and Purification 
SDG lyophilisate (22 g, 80% purity fraction obtained in Section 3.1.5) was hydrolyzed in 
the presence of 1M HCl in 70% methanol at 95°C. The reaction was monitored by injecting 
neutralized samples onto the UPLC and determining the content of SDG and SECO (Table 
3.1.5). The reaction was stopped by adding 50% NaOH to pH=8 when there was no further 
increase in SECO concentration as indicated by UPLC. Hydrolysis products were further 
purified and separated on a low-pressure column (C18 packing material, 55-110 µm) by washing 
with a water-methanol mixture with gradual increase of organic content from 5% to 90%. Two 
fractions of interest were obtained (75% and 40% SECO content), which were further purified on 
the preparative column as above (Tables 3.1.2-3.1.3). Fractions collected were evaporated to 
dryness, dissolved in Millipore water, and freeze-dried. In the process of purification SECO 
concentration was controlled by UPLC (Table 3.1.5).  
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3.2 Development and Validation of an HPLC Method with Fluorescence 
Detection for Quantification of Secoisolariciresinol (SECO), Enterolactone 
(EL) and Enterodiol (ED) in Rat Serum. 
3.2.1 Chemicals 
HPLC grade enterodiol, enterolactone, and 7-hydroxycoumarin (7-HC) were purchased 
from Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada). Secoisolariciresinol was produced and 
purified by myself in Dr. Muir’s lab in Agriculture and Agri-Food Canada, Saskatoon Research 
Center, SK (≥95% purity, confirmed by UPLC-MS). Acetonitrile HPLC grade was purchased 
from EMD Chemicals Inc. (Gibbstown, NJ, USA). Water was purified using a MilliQ Synthesis 
system (Millipore, Bedford, MA, USA). All other chemicals were of analytical grade. 
 
3.2.2 High Performance Liquid Chromatography (HPLC) Conditions 
The chromatographic system used for analysis was an Agilent Technologies 1200series 
(Agilent Technologies Inc., Mississauga, ON, Canada) with a Quaternary Pump (G1311A), 
Degasser (G1322A), Autosampler (G1329A), TCC (G1316A), and Fluorescence Detector 
(G1321A). Chromatographic separation was achieved with a Waters Symmetry C18 reversed-
phase column (4.6×150 mm, 5 μm particle size, Waters Corporation, Milford, MA, USA). The 
column was kept at 25°C. Wavelengths monitored were 277 nm for excitation and 617 nm for 
emission. Analytes were separated under gradient mobile phase conditions (Table 3.2.1) with a 
mobile phase that consisted of 0.1% formic acid in Millipore water and 0.1% formic acid in 
acetonitrile, at a flow rate of 1 mL/min and injection volume 50 μL. The column was washed 
with water:methanol (50:50) after every use. 
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Table 3.2.1 HPLC mobile phase linear gradient conditions for 
secoisolariciresinol (SECO), enterodiol (ED), and enterolactone (EL) 
separation 
 
Time 
(min) 
0.1% formic acid in 
water (%) 
0.1% formic acid in 
acetonitrile (%) 
0 85 15 
12 50 50 
14 10 90 
18 10 90 
20 85 15 
25 85 15 
 
3.2.3 Preparation of Standard Curve Solutions 
Primary stock solutions (1 mg/mL) of SECO, ED, EL and 7-HC, as internal standard (IS), 
were prepared in methanol and stored at -20°C. Mixed working solutions of SECO, ED and EL 
were prepared by serial dilution of primary stocks with water-acetonitrile (70:30) mixture in the 
range 0.1-100 μg/mL. Working stock solution of 7-HC (100 μg/mL) was prepared from primary 
stock solution using water-acetonitrile (70:30) mixture as a solvent. Quality control (QC) 
working solutions presenting the entire range of standard curve: lower limit of quantification 
(LLOQ), 3-fold the LLOQ low QC sample (LQC), near the center (MQC), and near the upper 
boundary of standard curve (HQC), were prepared using water-acetonitrile (70:30) mixture as a 
solvent (Table 3.2.1). 
 
Table 3.2.2 Concentrations of secoisolariciresinol (SECO), enterodiol (ED), and 
enterolactone (EL) used for preparation of QC working solutions 
 
Compound LLOQ 
(ng/mL) 
LQC 
(ng/mL) 
MQC 
(μg/mL) 
HQC 
(μg/mL) 
SECO 100 300 40 80 
ED 100 300 40 80 
EL 500 1500 40 80 
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To prepare the standard curve, 10 μL of working solutions was added to 90 μL of blank 
rat serum to achieve calibration standard curve range of 10 ng/mL-10 μg/mL for SECO and ED, 
and 50 ng/mL-10 μg/mL for EL. QC samples were prepared by spiking 90 μL of blank rat serum 
with 10 μL of QC working solutions. 
 
3.2.4 Extraction Procedure 
To 100 μL of serum, calibration standards or QC samples 10 μL of the working stock of 
IS, and 4 mL of diethyl ether were added. The mixture was vortexed for 10 min, followed by 
centrifugation (3200 rpm; 4°C) for 10 min in an Eppendorf centrifuge (Model 5804, Brinkman 
Instruments Inc., Westbury, NY, USA). The aqueous portion of the centrifuged sample was snap 
frozen in liquid nitrogen and the organic layer was transferred into disposable 16×100 mm glass 
tubes and dried down in a CentriVap Concentrator (Labconco Co., Kansas City, MO, USA) 
under vacuum at 50°C for 30min. Samples were reconstituted in 100 μL of water-acetonitrile 
(70:30) mixture, vortexed for 1.5 min, transferred into HPLC vials and injected (50 μL) onto the 
HPLC system. 
 
3.2.5 Method Validation 
Method validation was performed according to FDA guidelines145. The following 
validation parameters have been assessed: specificity, linearity and range, limit of detection, 
limit of quantification, recovery, accuracy and precision.  
Method specificity was tested by analyzing six different sources of rat serum to ensure 
the absence of endogenous compounds with the same retention times as SECO, ED, and EL. A 
10-point calibration curve in the range 10 ng/mL-10 μg/mL for SECO and ED, and 50 ng/mL-10 
μg/mL for EL (blank and zero samples were also included) was constructed to evaluate linearity 
of the method. The peak area ratios between analytes and IS were plotted against the nominal 
concentration of analytes. A linear least-squares regression analysis with weighting (1/x2) was 
applied to determine slope, intercept and coefficient of determination (r2).  
The accuracy and precision of the method were determined by analysis of the QC 
samples. The intra-day accuracy and precision were assessed by analysis of six replicates of QC 
samples (LQC, MQC, and HQC) on a single assay day. The inter-day accuracy and precision 
were determined from the same QC samples analyzed on three consecutive days (n=18). 
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Accuracy (%) was expressed as [(actual concentration/expected concentration)*100], and 
precision was expressed as % relative standard deviation (R.S.D.). 
The limit of detection (LOD) was defined as the lowest detectable concentration, taking 
into consideration a signal-to-noise ratio of 3. The lower limit of quantification (LLOQ) was 
determined at the lowest concentration at which the precision and accuracy were within 20% of 
the mean and true value, respectively. 
The recovery of analytes was determined by comparison of peak areas obtained by 
analysis of QC samples prepared in serum followed by extraction procedure and QC samples 
prepared in mobile phase (n=6). 
 
3.3 Assessment of the Pharmacokinetics (PK) of Secoisolariciresinol (SECO) 
After Single Intravenous (IV) and Oral Bolus Administration in Rat 
3.3.1 Chemicals 
Enterodiol (HPLC grade), enterolactone (HPLC grade), 7-hydroxycoumarin (HPLC 
grade), polyethylene glycol 300 (PEG 300), benzyl alcohol, Tween 80, and ethanol, all analytical 
grade, β-glucuronidase sulfatase from Helix Pomatia (G1512) were purchased from Sigma-
Aldrich Canada Ltd. (Oakville, ON, Canada). Secoisolariciresinol was produced and purified by 
myself in Dr. Muir’s lab in Agriculture and Agri-Food Canada, Saskatoon Research Center, SK 
(≥95% purity, confirmed by UPLC-MS). Acetonitrile HPLC grade was purchased from EMD 
Chemicals Inc. (Gibbstown, NJ, USA). Water was purified using a MilliQ Synthesis system 
(Millipore, Bedford, MA, USA). All other chemicals were of analytical grade. 
 
3.3.2 Animals 
Wistar male rats weighing 260-320g (n=18) were obtained from Charles River Canada 
(St. Constant, PQ, Canada). For the pilot studies Wistar male rats weighing 350-400g (n=4) were 
obtained from the Animal Resources Centre of the University of Saskatchewan (Saskatoon, SK, 
Canada). Animals were housed in groups of two at a controlled temperature and were maintained 
on a 12 hour dark-light cycle. The animals received a standard laboratory rat chow and water ad 
libitum throughout the acclimatization period (one week). This work was approved by the 
Univeristy of Saskatchewan’s Animal Research Ethics Board, and adhered to the Canadian 
Council on Animal Care guidelines for humane animal use. 
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3.3.3 Secoisolariciresinol (SECO) Dosing Vehicle 
The following mixture was used as a dosing vehicle for SECO intravenous and oral 
administration to rats: polyethylene glycol 300, Tween 80, benzyl alcohol, and ethanol in 
proportion 65:8:3:24 by volume, considering SECO’s poor water solubility. SECO concentration 
in prepared vehicle was 20 mg/mL. 
 
3.3.4 The 24-hour (Sampling Schedule Optimization) and the 11-hour Pilot Studies 
(Glucuronidase Pretreatment) 
For the 24-hour pilot study a single dose of SECO (40mg/kg) was administered to the rat 
(n=1) by oral gavage (18 gauge × 3 in). Blood (250 μL) was collected into a plastic 
microcentrifuge tube (0.65 mL) via saphenous venepuncture at 0 (pre-dose), 15, 30, 45, 60, 90 
min, and 2, 3, 7, 11 and 24 hours after the dosing.  
For the 11-hour study a single dose of SECO (40 mg/kg) was administered to the rat 
(n=1) by oral gavage (18 gauge × 3 in). Blood (500μL) was collected into a plastic 
microcentrifuge tube (0.65 mL) via saphenous venepuncture at 0 (pre-dose), 30 min, 60 min, and 
2, 3, 7, and 11 hours after the dosing. 
The animals were fasted for 10 hours prior to the dose administration and were given 
food 3 hours after the dosing. The animals were terminated after completion of the study under 
isoflurane anaesthesia by opening chest cavity and cutting the left ventricle of the heart. 
 
3.3.5 Rat Jugular and Femoral Vein Cannulation (36-hour Pilot, 12-hour, and 48-hour Studies) 
In order to take blood samples and to dose animals, either jugular or jugular and femoral 
vein cannulation was performed 24 hours prior to the study. Briefly, vascular cannulas (Silastic 
tubing, I.D. x O.D. (0.64 mm x 1.19 mm), Dow Corning Co., Midland, MI, USA) were 
implanted into the rat right jugular and left femoral veins under the isoflurane anaesthesia. For 
the orally dosed animals only the right jugular vein was cannulated. The cannulas were passed 
subcutaneously to the cannulation site through the skin incision in the dorsal cervical area of the 
animal. A 500 IU/mL heparin in 0.9% saline was instilled into the cannulas to prevent clotting. 
Rats were closely monitored to insure their full recovery after the surgery. 
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3.3.6 The 36-hour Pilot Study 
A single dose of SECO (20 mg/kg) was administered via oral gavage (18 gauge × 3 in) or 
intravenously via a femoral vein cannula (one animal for each route of administration). The 
animals were fasted for 10 hours prior to the dose administration and were given food 3 hours 
after the dosing. Blood (250 μL) was drawn through the jugular cannula into a plastic 
microcentrifuge tube (0.65 mL) at 0 (pre-dose), 5, 10, 15, 20, 30, 45, 60 min, and 2, 4, 8, 12, 18, 
24, and 36 hours after the dosing. After each blood sample the same amount of 0.9% saline was 
injected into the jugular cannula to replace the fluid loss. The animals were terminated after 
completion of the study under isoflurane anaesthesia by opening chest cavity and cutting the left 
ventricle of the heart.  
 
3.3.7 The 12-hour Pharmacokinetic Study 
A single dose of SECO was administered via oral gavage (18 gauge × 3 in) (40 mg/kg) or 
intravenously (20 mg/kg) via a femoral vein cannula (six animals for each route of 
administration). The parallel study design was preferable for the experiment due to the risk of the 
catheter blockage during the wash-out period between the different routes of administration. The 
animals were fasted for 10 hours prior to the dose administration and were given food 3 hours 
after the dosing. Blood (250 μL) was drawn through the jugular cannula into a plastic 
microcentrifuge tube (0.65 mL) at 0 (pre-dose), 5, 10, 15, 20, 30, 45, 60 min, and 2, 4, 8, and 12 
hours after the dosing. After each blood sample the same amount of 0.9% saline was injected 
into the jugular cannula to replace the fluid loss. The animals were terminated after completion 
of the study under isoflurane anaesthesia by opening chest cavity and cutting the left ventricle of 
the heart.  
 
3.3.8 The 48-hour Pharmacokinetic Study 
A single dose of SECO was administered via oral gavage (18 gauge × 3 in) (40 mg/kg) or 
intravenously (20 mg/kg) via a femoral vein cannula (three animals for each route of 
administration). The parallel study design was preferable for the experiment due to the risk of the 
catheter blockage during the wash-out period between the different routes of administration. The 
animals were fasted for 10 hours prior to the dose administration and were given food 3 hours 
after the dosing. Blood (250 μL) was drawn through the jugular cannula into a plastic 
microcentrifuge tube (0.65 mL) at 0 (pre-dose), 8, 10, 12, 15, 18, 21, 24, 30, 36, 42, and 48 hours 
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after the dosing. After each blood sample the same amount of 0.9% saline was injected into the 
jugular cannula to replace the fluid loss followed by 500 IU/mL heparin in 0.9% saline 
instillation to prevent clotting. The animals were terminated after completion of the study under 
isoflurane anaesthesia by opening chest cavity and cutting the left ventricle of the heart.  
 
3.3.9 Serum Preparation 
Blood samples were allowed to clot for 30 min at a room temperature and were then 
centrifuged in an Eppendorf centrifuge (Model 5417C, Brinkman Instruments Inc., Westbury, 
NY, USA) at 3500 rpm for 5 min. Separated serum was transferred into 0.65 mL plastic 
microcentrifuge tubes and was stored at -80°C until analysis. 
 
3.3.10 Glucuronidase/Sulfatase Sample Pretreatment for the 11-hour Pilot Study 
In order to measure total concentration of SECO, ED, and EL in rat serum after SECO 
administration, samples were incubated with a freshly prepared mixture of β-glucuronidase 
sulfatase from Helix Pomatia in 0.5 mol/L (pH 5.0) sodium acetate buffer as reported113 prior to 
HPLC analysis. 100 µL of sodium acetate buffer (0.1 mol/L, pH 5.0) and 20 µL of enzyme 
mixture (100 g/L) were added to 100 µl of serum. The mixture was then incubated in a shaking 
water bath at 37°C for 4 hours followed by the extraction with diethyl ether as described in 
Section 3.2. 
 
3.3.11 High Performance Liquid Chromatography (HPLC) Analysis 
The HPLC method with fluorescence detection described in Section 3.2 was used for the 
serum sample analysis. A standard curve was constructed every time prior to analysis. QC 
samples were analyzed with each analysis run as acceptance criteria for each run. 
 
3.3.12 SECO Pharmacokinetic Parameter Estimation and Statistical Analysis 
Non-compartmental methods were used for assessment of SECO PK parameters based on 
the results of the 12-hour study. GraphPad Prism 4.0 (GraphPad software, San Diego, CA, USA) 
and Excel were used for calculations. PK parameters are expressed as mean ± SD. 
The area under the curve (AUC) and the area under the first moment curve (AUMC) 
defined by equations 3.3.1 and 3.3.2 were calculated using trapezoidal rule. 
AUC =        (Equation 3.3.1) ∫∞ ×0 )( dttC
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AUMC = ,      (Equation 3.3.2) ∫∞ ××0 )( dttCt
where C(t) is SECO serum concentration (ng/mL) at time t (hours).  
The mean residence time (MRT) was calculated as ratio of AUMC and AUC (Equation 
3.3.3). 
MRT = 
AUC
AUMC        (Equation 3.3.3) 
Systemic clearance (ClS) was determined as dose over AUC following IV SECO 
administration: 
ClS = 
IVAUC
DOSE        (Equation 3.3.4) 
Elimination rate constant (k) was determined as a slope of the terminal part of the semi-
logarithmic plot (SECO concentration versus time after single IV bolus). 
An apparent volume of distribution at steady state (VSS) was determined as product of 
systemic clearance and MRT after SECO single IV bolus: 
VSS =        (Equation 3.3.5) IVS MRTCl ×
Volume of distribution was also determined using following equation: 
Vd = 
IVAUCk
DOSE
×        (Equation 3.3.6) 
 
SECO half-life (t1/2) was determined as follows: 
t1/2 =        (Equation 3.3.7) IVMRT×693.0
Alternatively SECO half-life (t1/2) was determined as follows: 
t1/2 = k
693.0         (Equation 3.3.8) 
SECO oral bioavailability (FORAL) was calculated using the following equation: 
FORAL = 
ORALIV
IVORAL
DOSEAUC
DOSEAUC
×
×
,     (Equation 3.3.9) 
where AUCIV is the mean of results for the animals dosed intravenously (n=6) and 
AUCORAL is the mean of results for the animals dosed orally (n=6), DOSEIV is 20 mg/kg and 
DOSEORAL is 40 mg/kg. 
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4. RESULTS 
4.1 Isolation of SDG and SECO From 40% Flaxseed Lignan Starting Material 
The preparative process yielded 15 g of SDG (≥95% purity) from the starting material 
containing 40% of SDG (140g). The purity of compound was determined by UPLC analysis on 
the basis of the area percentage of the peak absorbed at 280 nm (Figure 4.1.1). 
SECO was produced from SDG by acid hydrolysis. SDG was firstly converted into 
secoisolariciresinol monoglucoside (SMG), which was then hydrolyzed to SECO. It was 
important to monitor concentration of SECO in the reaction mixture as SECO molecule is not 
stable under the applied conditions and could be transformed to its anhydrous form 
anhydrosecoisolariciresinol (ASECO), depending on the duration of hydrolysis and acid 
concentration. Final concentrations of the hydrolysis products based on the area percentage of 
peaks absorbed at 280 nm were SDG 3.5%, SMG 23%, SECO 23%, ASECO 30% (identity of 
compounds was confirmed  by comparison with chromatograms of authentic standards).  
The acid hydrolysis procedure yielded 1.83 g of SECO (≥95% purity) from 22 g of SDG 
(80% purity) starting material. The purity of SECO was determined by UPLC analysis on the 
basis of the area percentage of the peak absorbed at 280 nm (Figure 4.1.2). 
Identity of purified SDG and SECO was also confirmed by quadrupole time-of-flight 
mass spectrometry in negative ionization mode which exhibited ions at m/z 685.2 and 361.1, 
corresponding to [M-H]- ions for SDG and SECO. 
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Figure 4.1.1 Representative UPLC chromatogram of purified SDG (absorbance at 280 nm) with 
retention time 0.83 min (UPLC chromatographic conditions are indicated in Section 3.1). 
 
 
 
 
Figure 4.1.2 Representative UPLC chromatogram of purified SECO (absorbance at 280 nm) 
with retention time 1.38 min (UPLC chromatographic conditions are indicated in Section 3.1). 
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4.2 Development and Validation of an HPLC Method with Fluorescence 
Detection for Quantification of Secoisolariciresinol (SECO), Enterolactone 
(EL) and Enterodiol (ED) in Rat Serum. 
Typical chromatograms of blank serum and serum spiked with working solutions of 
SECO, ED, EL, and IS demonstrate that there are no endogenous peaks that could interfere with 
analytes and the method is specific under the specified chromatographic conditions. The 
retention times for IS, SECO, ED, and EL are 7.0, 7.9, 9.4, and 12.3 min, respectively (Figure 
4.2.1). 
 
 
(a) 
min0 2.5 5 7.5 10 12.5 15 17.5 20 22.5
LU    
0.5
1
1.5
2
 FLD1 A, Ex=277, Em=617 (VALERY MAY21\ZS 1.D)
IS 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 min0 2.5 5 7.5 10 12.5 15 17.5 20 22.5
LU    
0.5
1
1.5
2
 FLD1 A, Ex=277, Em=617 (VALERY MAY21\7-1.D)
IS 
EL
SECO
ED
Figure 4.2.1 Representative HPLC chromatograms: (a) blank rat serum spiked with internal 
standard; (b) blank rat serum spiked with mixed working solution (1 μg/mL) of SECO (7.9 min), 
ED (9.4 min), EL (12.3 min) and internal standard (7.0 min).  
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The LOD for SECO, ED, and EL are 3 ng/mL, 3 ng/mL, and 12 ng/mL, respectively. The 
LLOQ was determined to be 10 ng/mL (SECO), 10 ng/mL (ED), 50 ng/mL (EL) with acceptable 
accuracy (80-120%) and precision (R.S.D. < 20%). The calibration curves of the peak area ratios 
versus analytes concentration showed good linear responses over a wide range of concentrations 
(10 ng/mL-10 μg/mL). Coefficients of determination were greater than 0.99, relevant slope 
values were statistically different from 0 (P<0.001), while intercepts were not significantly 
different from zero (Student’s t-test, P<0.05, Prism 4.0, GraphPad software, San Diego, CA, 
USA) (Table 4.2.1). 
 
Table 4.2.1 Linearity data for the determination of SECO, ED, and EL with the proposed HPLC 
method 
 
SECO calibration curve ED calibration curve EL calibration curve 
slope intercept r2 slope intercept r2 slope intercept r2 
0.000460 
0.000469 
0.000445 
-0.00027 
-0.00063 
-0.00049 
0.996 
0.993 
0.990 
0.001002
0.001015
0.000974
-0.00119 
 0.00119 
-0.00002 
0.999
0.997
0.999
0.000218 
0.000207 
0.000191 
-0.00183 
-0.00144 
 0.00033 
0.997 
0.995 
0.996 
mean         
0.000458 -0.00046 0.993 0.000997 -0.000004 0.998 0.000205 -0.00098 0.996 
S.D.         
0.00001 0.00010 0.002 0.00001 0.000689 0.001 0.000008 0.00066 0.001 
  S.D.: standard deviation of the mean 
 
During the method validation intra- and inter-day precisions were less than 10% and the 
accuracy of estimated analytes concentrations ranged from 93 to 110% (Tables 4.2.2-4.2.4). The 
mean (±SD) recoveries of SECO at 30 ng/mL, 4 μg/mL, and 8 μg/mL were 106±6.8%, 
105±0.5%, and 108±1.1%, respectively; of ED at 30 ng/mL, 4 μg/mL, and 8 μg/mL were 
108±4.7%, 105±0.7%, and 109±1.2%, respectively; of EL at 150 ng/mL, 4 μg/mL, and 8 μg/mL 
were 102±3.9%, 98.7±0.7%, and 102±1.3%, respectively. 
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Table 4.2.2 Intra-day (n=6) and inter-day (three consecutive days) accuracy and precision 
values of SECO determination by proposed HPLC method in rat serum 
 
Intra-day accuracy and precision Inter-day accuracy and precision SECO 
nominal 
concentration 
in QCs 
(μg/mL) 
Observed 
concentration 
(mean±S.D., 
μg/mL) 
Accuracy 
(%) 
Precision 
(CV%) 
Observed 
concentration 
(mean±S.D., 
μg/mL) 
Accuracy 
(%) 
Precision 
(CV%) 
0.03 
4 
8 
0.030±0.002 
4.31±0.14 
7.87±0.38 
100.3 
107.6 
98.3 
7.1 
3.16 
4.83 
0.030±0.001 
4.29±0.11 
7.88±0.47 
101 
107 
98.5 
5.48 
2.57 
5.99 
 
 
 
 
 
 
 
Table 4.2.3 Intra-day (n=6) and inter-day (three consecutive days) accuracy and precision 
values of ED determination by proposed HPLC method in rat serum 
 
Intra-day accuracy and precision Inter-day accuracy and precision ED nominal 
concentration 
in QCs 
(μg/mL) 
Observed 
concentration 
(mean±S.D., 
μg/mL) 
Accuracy 
(%) 
Precision 
(CV%) 
Observed 
concentration 
(mean±S.D., 
μg/mL) 
Accuracy 
(%) 
Precision 
(CV%) 
0.03 
4 
8 
0.032±0.0006 
4.16±0.18 
8.43±0.216 
105.2 
104 
105.3 
1.93 
4.33 
2.57 
0.031±0.0008
4.08±0.14 
8.40±0.40 
106.2 
101.9 
105 
2.43 
3.41 
4.72 
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Table 4.2.4 Intra-day (n=6) and inter-day (three consecutive days) accuracy and precision 
values of EL determination by proposed HPLC method in rat serum 
 
Intra-day accuracy and precision Inter-day accuracy and precision EL nominal 
concentration 
in QCs 
(μg/mL) 
Observed 
concentration 
(mean±S.D., 
μg/mL) 
Accuracy 
(%) 
Precision 
(CV%) 
Observed 
concentration 
(mean±S.D., 
μg/mL) 
Accuracy 
(%) 
Precision 
(CV%) 
0.15 
4 
8 
0.147±0.009 
3.90±0.28 
8.37±0.35 
98.2 
97.6 
104.5 
6.43 
7.11 
4.72 
0.152±0.008 
3.99±0.24 
8.58±0.40 
101.7 
99.9 
107.2 
5.66 
6.11 
4.63 
 
Collectively the data suggest that the new gradient reversed-phase HPLC method with 
fluorescence detection is suitable for the simultaneous determination of lignans in rat serum. The 
analytical method is specific, sensitive, accurate and precise for the quantification of SECO, ED, 
and EL. The total analytical run time is 25 min, which allows us to analyze multiple samples in a 
relatively short time period. The method is suitable for pharmacokinetic studies which require 
both sensitive (to detect and quantify small changes in drug concentration over time) and simple 
(high number of samples to be processed) analytical techniques. 
 
 
4.3 Assessment of the Pharmacokinetics (PK) of Secoisolariciresinol (SECO) 
After Single Intravenous (IV) and Oral Bolus Administration in Rat 
4.3.1 The 24-hour (Sampling Schedule Optimization) and the 11-hour Pilot Studies 
(Glucuronidase Pretreatment) 
A 24-hour pilot study was performed to optimize blood sampling schedule. The 
maximum SECO concentration (309.4 ng/mL) was observed 15 min after the oral administration 
(40 mg/kg) with gradual decrease to 46 ng/mL 24 hours after the dosing. ED was detected in the 
24-hour sample, while EL was not detected. 
The 11-hour pilot study was performed to compare total and free lignans after SECO 
single oral dose administration (40 mg/kg). 100 µL of serum at each time point was purified and 
subjected to HPLC analysis as described in Section 3.2 to monitor free lignan concentration in 
41 
rat serum over time. The other portion of serum of the same time point sample was incubated 
with glucuronidase before the HPLC analysis to hydrolyze lignan conjugates and to observe 
changes in total lignan concentration over time.  
The first spike of free SECO concentration in serum was observed in 30-min sample 
(346.5 ng/mL) with two additional peaks at 2 hours (320.5 ng/mL) and 11 hours (620 ng/mL) 
after the dose administration. ED was detected (levels were below the limit of quantification) in 
7 and 11 hour samples. 
The HPLC analysis of the pre-dose 0 min sample after treatment with glucuronidase 
showed significant peaks at 7.9 min and 12.3 min, time corresponding to SECO and EL elution, 
which could be a result of deconjugated compounds with similar retention times from rat diet 
and should be confirmed by other methods of analysis. 
 
4.3.2 The 36-hour Pilot Study 
Taking into consideration results of the 24-hour study, a 36-hour pilot study was 
performed to further optimize blood sampling schedule after IV and oral SECO administration to 
allow for the appropriate detection of ED and EL. 
The maximum serum SECO concentration (5180 ng/mL) was observed 5 min after the IV 
SECO administration (20 mg/kg). The serum SECO levels dropped drastically to 276 ng/mL 
after 1 hour, and to 11 ng/mL at the end of experiment. ED was detected starting from the 12-
hour sample and was quantified in 18-hour (15.5 ng/mL) and 24-hour (12.3 ng/mL) samples. EL 
was detected only at 18 and 24 hours after SECO IV administration. 
The maximum serum SECO concentration (181.9 ng/mL) was observed 5 min after the 
oral SECO administration (20 mg/kg). SECO serum concentration dropped to 11.7 ng/mL at 4 
hours after the dose and was not detected in later samples. ED was detected only in the 8- and 
12-hour samples. EL was not detected in the rat serum after SECO oral administration. 
 
4.3.3 The 12-hour Pharmacokinetic Study 
A 12-hour study was performed to assess SECO concentration profile, based on the 
results of pilot studies. SECO serum concentration dropped quickly during the first hour after IV 
administration and by 12 hours concentrations were near the LOQ of the assay. ED was detected 
(levels were below the LOQ of the assay) at 12 hours after IV administration in rats 1, 2, and 4; 
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and in rats 1, 3, 6 after oral administration. EL was not detected. Tables 4.3.1 and 4.3.2 
summarize results of the 12-hour study. 
 
Table 4.3.1 Serum concentration versus time profile of SECO after single IV bolus  
(20 mg/kg) to male Wistar rats (n=6) 
 
Time 
(min) 
Rat 1 
(ng/mL) 
Rat 2 
(ng/mL) 
Rat 3 
(ng/mL) 
Rat 4 
(ng/mL) 
Rat 5 
(ng/mL) 
Rat 6 
(ng/mL) 
0 0 0 0 0 0 0 
5 4489.83 4156.7 9047.51 5313.25 4666.3 5864.07 
10 1714.89 2321.08 5014.24 3177.41 2353.68 3180.65 
15 1304.91 1223.61 2643.07 1651.05 1616.75 1626.48 
20 855.3 885.37 1827.32 1620.21 955.8 N/A 
30 408.76 525.76 921.82 654.84 410.11 420.27 
45 183.71 219.56 345.52 259.7 221.55 235.39 
60 186.35 165.01 123.13 214.11 138.34 185.72 
120 186.98 130.19 35.26 137.69 147.09 141.47 
240 D 117.01 17.48 78.3 52.2 D 
480 N/D 58.93 78.71 75.81 N/D N/D 
720 N/D N/D 24.19 D N/D 30.08 
D – detected (below the LOQ of the assay) 
N/D – not detected 
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Table 4.3.2 Serum concentration versus time profile of SECO after single oral dose  
(40 mg/kg) to male Wistar rats (n=6) 
 
Time 
(min) 
Rat 1 
(ng/mL) 
Rat 2 
(ng/mL) 
Rat 3 
(ng/mL) 
Rat 4 
(ng/mL) 
Rat 5 
(ng/mL) 
Rat 6 
(ng/mL) 
0 0 0 0 0 0 0 
5 124.23 448.96 315.23 97.35 119.2 40.38 
10 216.63 240.56 655.55 90.26 651.38 102.93 
15 189.62 163.63 1487.26 67.08 811.57 43.38 
20 166.75 109.28 565.56 42.97 N/A N/A 
30 187.99 54.4 301.38 59.63 398.78 37.38 
45 297.03 146.24 195.68 102.49 244.04 50.2 
60 355.94 140.34 1040.28 152.9 238.37 63.98 
120 106.18 81.39 52.71 82.99 74.14 87.84 
240 44.07 46.46 102.54 101.57 11.01 D 
480 97.21 105.7 73.05 93.15 D 48.49 
720 17.14 N/A 150.04 88.38 13.45 30.08 
D – detected (below the LOQ of the assay) 
N/D – not detected 
N/A – not available 
 
 
Figure 4.3.1 suggests that SECO exhibits two compartment model characteristics with an 
extensive distribution phase. SECO concentration profile after oral administration is shown on 
Figure 4.3.2. 
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Figure 4.3.1 SECO serum concentration profile after single IV dose (20mg/kg) in six 
male Wistar rats: (a) rectilinear plot; (b) semilogarithmic plot (  rat 1, rat 2, 
rat 3,  rat 4,  rat 5, rat 6).  
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Figure 4.3.2 SECO serum concentration profile after single oral dose (40mg/kg) in six 
male Wistar rats: (a) rectilinear plot; (b) semilogarithmic plot (  rat 1, rat 2, 
rat 3,  rat 4,  rat 5, rat 6).  
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4.3.4 The 48-hour Pharmacokinetic Study 
A 48-hour study was conducted to assess SECO, ED and EL concentration profile, based 
on the results of pilot studies indicating that ED is detectable starting 12 hours after the SECO 
administration and EL is detectable starting 18 hours after the SECO administration. Tables 4.3.3 
and 4.3.4 summarize results of the 48-hour study.  
 
Table 4.3.3 Serum concentration versus time profile of SECO after single oral (40 mg/kg by 
gastric gavage) and IV (20 mg/kg via femoral cannula) in male Wistar rats (n=3 per dosing 
route) 
 
Time 
(hours) 
Rat 1 IV 
(ng/mL) 
Rat 2 IV 
(ng/mL) 
Rat 3 IV 
(ng/mL) 
Rat 4 oral 
(ng/mL) 
Rat 5 oral 
(ng/mL) 
Rat 6 oral 
(ng/mL) 
0 0 0 0 0 0 0 
8 114.47 66.82 97.18 111.47 detect 67.31 
10 86.8 92.41 88.5 66.64 13.87 69.35 
12 38.85 55.1 50.63 68.99 22.19 82.81 
15 27.58 49.02 22.84 50.64 221.84 23.76 
18 D D N/D 21.15 125.67 71.19 
21 D D D D 107.43 19.37 
24 N/D N/D D N/D 124.55 D 
30 N/D N/D N/D N/D 45.81 N/D 
36 N/D N/D N/D N/D 46.1 N/D 
42 N/D N/D N/D N/D D N/D 
48 N/D N/D N/D N/D N/D N/D 
 D – detected (below the LOQ of the assay) 
N/D – not detected 
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Table 4.3.4 Serum concentration versus time profile of ED after single oral (SECO, 40 
mg/kg by gastric gavage) and IV (SECO, 20 mg/kg via femoral cannula) in male Wistar rats 
(n=3 per dosing route) 
 
Time 
(hours) 
Rat 1 IV 
(ng/mL) 
Rat 2 IV 
(ng/mL) 
Rat 3 IV 
(ng/mL) 
Rat 4 oral 
(ng/mL) 
Rat 5 oral 
(ng/mL) 
Rat 6 oral 
(ng/mL) 
0 0 0 0 0 0 0 
8 D N/D D N/D N/D D 
10 D D D D D N/D 
12 N/D N/D D 11.48 N/D N/D 
15 D D D D N/D D 
18 D D D D D D 
21 11.94 13.28 14.48 D D D 
24 D 12.15 D D N/D D 
30 N/D N/D N/D N/D N/D D 
36 N/D N/D N/D N/D D N/D 
42 N/D N/D N/D N/D D N/D 
48 N/D N/D N/D N/D D N/D 
 D – detected (below the LOQ of the assay) 
N/D – not detected 
 
EL was detected in 15, 18, and 36 hours samples of rat 1 (IV dose). It was also detected 
in 21 and 36 hours sample of rat 4 (oral dose). 
SECO concentration versus time is also depicted in Figure 4.3.3. 
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Figure 4.3.3 SECO serum concentration profile in male Wistar rats after: (a) IV bolus (20 
mg/kg, n=3); (b) oral administration (40 mg/kg, n=3) (  rat 1, rat 2, rat 3, 
 rat 4,  rat 5, rat 6).  
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4.3.5 SECO Pharmacokinetic Parameter Estimation 
Non-compartmental methods were used for assessment of SECO PK parameters based on 
the results of the 12-hour study.  
Tables 4.3.5 and 4.3.6 summarize SECO PK parameters calculated using mean residence 
time and elimination rate constant. 
 
Table 4.3.5 SECO PK parameter estimation based on the results of 12-hour study after single IV 
(20 mg/kg) or oral (40 mg/kg) dose of SECO (MRT used for determination Vss and t1/2) 
 
IV Oral Route 
of 
admin 
Weight 
(g) 
AUCIV 
(ng×h/mL) 
AUMCIV 
(ng×h2/mL)
MRTIV 
(h) 
ClS 
(L/h)
VSS 
(L) 
t1/2 
(h) 
Weight 
(g) 
AUCORAL 
(ng×h/mL)
Rat 1 315 1298 498 0.38 4.85 1.86 0.27 280 1116
Rat 2 310 1870 3060 1.64 3.31 5.42 1.13 310 693
Rat 3 275 2856 3916 1.37 1.93 2.64 0.95 320 2016
Rat 4 300 2246 2999 1.34 2.67 3.56 0.92 260 1139
Rat 5 260 1556 959 0.62 3.34 2.06 0.43 285 714
Rat 6 285 2517 3684 1.46 2.26 3.31 1.01 280 695
    
Mean  2057 3.06 3.15 0.79  1062
S.D.  591 1.04 1.30 0.35  512
S.D.: Standard deviation 
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Table 4.3.6 SECO PK parameter estimation based on the results of 12-hour study after single IV 
(20 mg/kg) or oral (40 mg/kg) dose of SECO (k used for determination of Vd and t1/2) 
 
IV Oral Route of 
admin Weight 
(g) 
AUCIV 
(ng×h/mL) 
k  
(h-1) 
ClS  
(L/h) 
Vd  
(L)
t1/2  
(h) 
Weight 
(g) 
AUCORAL 
(ng×h/mL) 
Rat 1 315 1298 0.33 4.85 14.50 2.07 280 1116
Rat 2 310 1870 0.16 3.31 20.92 4.37 310 693
Rat 3 275 2856 0.06 1.93 32.57 11.72 320 2016
Rat 4 300 2246 0.16 2.67 16.43 4.26 260 1139
Rat 5 260 1556 0.39 3.34 8.53  1.76 285 714
Rat 6 285 2517 0.17 2.26 13.30 4.07 280 695
   
Mean  2057 0.21 3.06 17.71 4.71  1062
S.D.  591 0.12 1.04 8.33 3.62  512
S.D.: Standard deviation 
 Visual analysis of the semilogarithmic plot of SECO concentration versus time after 
single IV bolus suggests that calculation of volume of distribution and half-life using elimination 
rate constant will give more accurate results than using MRT. Mean Residence Time is a ratio of 
AUMC and AUC from time zero to infinity. As there are not enough points in the tail region of 
the SECO concentration versus time curve, computational error in estimation of the tail region 
(to time infinity) when calculating AUC and especially AUMC becomes high. 
 SECO PK parameters after single IV bolus are as follows: Cls=3.06±1.04 L/h, 
k=0.21±0.12 h-1, Vd=17.71±8.33 L, t1/2=4.71±3.62 h, and Foral=26 %. 
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5. DISCUSSION 
5.1 Isolation of SDG and SECO From 40% Flaxseed Lignan Starting Material 
The first objective of my research project was isolation of pure SDG and, subsequently 
SECO, as the latter is not readily available on the market in quantities sufficient for the 
pharmacokinetic study. Utilization of pure analyte is essential for pharmacokinetic evaluations, 
as coadministered substances might affect the rate of absorption, distribution and metabolism of 
the compound being analyzed. For naturally occurring substances, the effect of a biological 
matrix needs to be taken into consideration as well. For example, the degree to which flaxseed is 
crushed will affect the biovailability of ED and EL89. In healthy volunteers consuming the same 
amount of whole, crushed, or ground flaxseed, the mean relative bioavailability of ED and EL 
was only 28% from whole flaxseed and 43% from crushed flaxseed compared to ground 
flaxseed89. As well, high oil component of flaxseed might interfere with lignan absorption. 
The metabolic profile of the pure compound could be different from that in the dietary 
source. Flaxseed contains SDG in the form of lignan polymer (Section 2.2). It takes several hours 
before SDG is released from the macromolecule, deglycosylated to SECO and absorbed85. The 
process supposedly occurs in the ascending colon skipping the major absorption site, the small 
intestine146. Similarly, in healthy volunteers consuming sesame seeds, which contain both, SDG 
and SECO, maximum SECO concentration was achieved approximately 6 hours after oral 
administration121. On the other hand, pure SECO administered oraly, could be readily absorbed 
in the small intestine and would reach the systemic circulation faster (Section 4.3).  
A difference in urinary lignan excretion was also observed after a single oral 
administration of equimolar quantities of SDG and SECO in rats147. The 24-hour total lignan (the 
sum of SECO, ED and EL) urinary excretion after SECO administration was three-fold higher 
than following the SDG dose. EL and ED were the major lignans excreted after SECO 
administration, while mostly EL was excreted after SDG administration147. Chronic exposure to 
SECO also results in a drastic increase in EL urinary excretion, with ED being a minor 
metabolite in rat urine114. 
Although some PK studies were conducted with dietary source of lignans120,121, the 
method used to quantify SECO in food samples is another major factor that will affect the study 
outcome. As was reviewed in Section 2.6, flaxseed and other food samples need hydrolysis, 
before SECO could be quantified. All hydrolysis methods reported in the literature give up to 26-
fold variation in SECO concentration making calculation of the equivalent dose of the dietary 
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source of SECO very difficult122. Moreover, different food matrices require additional 
experiments for the optimization of the hydrolysis time140. Formation of artifacts during 
hydrolysis is another drawback of some methods of lignan analysis140. Therefore, caution should 
be exercised when interpreting results of such studies. Given these limitations I endeavoured to 
generate a highly pure source of SECO to ensure reliable PK evaluations. 
SECO was produced from SDG by acid hydrolysis with subsequent purification using 
preparative HPLC. During the reaction, SDG is firstly hydrolyzed to SMG and then SECO is 
formed. Unfortunately, with prolonged hydrolysis time, SECO breaks down to ASECO and its 
concentration in the reaction mixture starts to decrease3. Therefore, it was very important to 
monitor changes in SECO concentration during the process, and I had to stop the reaction at a 
maximum SECO content of 23%. After separation on the low-pressure column, two fractions of 
interest were chosen for further purification (SECO 75% and SECO 40%). Some difficulties 
were experienced during the purification of material with 40% SECO content, as it also 
contained considerable amount of SMG (55%). Due to similar physico-chemical properties SMG 
and SECO eluted very close together, which required extensive experimenting with gradient 
conditions to achieve better separation. Moreover, fluctuation of SECO retention time caused by 
the changes in the room temperature during the preparative HPLC, interfered with collection 
fractions with maximum SECO content. All above mentioned factors contributed to the low yield 
of pure SECO (10% of utilized SDG). The final purity of SECO was above 95% and the amounts 
generated were sufficient to carry out the necessary PK evaluations. 
 
5.2 Development and Validation of an HPLC Method with Fluorescence 
Detection for Quantification of Secoisolariciresinol (SECO), Enterolactone 
(EL) and Enterodiol (ED) in Rat Serum. 
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The second objective of my research was to develop and validate a method for lignan 
quantification suitable for pharmacokinetic applications. Although mass spectrometry offers high 
analytical sensitivity, it is not readily available in many laboratories. On the other hand, HPLC 
with UV detection commonly used for plant lignan samples lacks sensitivity when adapted to 
biological fluids138,143,144. Taking into consideration that lignans show high fluorescence 
intensity148,149, development of an HPLC method with fluorescence detection would give an 
advantage of higher sensitivity, necessary for PK studies. As few endogenous compounds of 
biological matrices have the ability to fluoresce, the method would be more specific as well. 
The developed method is suitable for quantification of SECO, ED, and EL in rat serum. 
While most of the reported methods determine ED and EL only95,125,131,134, as was reviewed in 
Section 2.5, only recently has SECO been included in the serum analysis129,130. Low serum 
volume (100 µL) requirements allow for serial blood sampling necessary for pharmacokinetic 
applications in small species like the rat. The extraction procedure used for the sample clean-up 
is relatively straightforward and simple, compared to ion-exchange chromatography and 
following derivatization in commonly used GC-MS methodology. To account for losses of the 
analytes during sample purification and evaporation of the solvent during analysis, 7-
hydroxycoumarin is used as an internal standard. On the other hand, most MS methods use 
deuterated or multiply 13C-labeled lignans which are not commercially available and need to be 
additionally synthetized115,127,128,132,133. Moreover, deuterated standards are often unstable and 
can loose deuterium while in solution. Deuterium could be replaced by hydrogen, which will 
result in a reduced amount of internal standard used for the sample processing and 
overestimation of the analyte128.  
A relatively short run time (25 min) of the developed method allows one to process more 
samples as opposed to some recently published methods which require up to 85 min for 
analysis129,130,148. The developed method does not have the high sensitivity of some HPLC 
methods utilizing coulometric electrode array detection, however, the accuracy and precision of 
these methods was reported to be low for SECO (66% accuracy, 37% presicion) and ED (69% 
accuracy, 44% precision) making them semiquantitave at the lower range of concentrations 
117,129.  
The developed HPLC method is specific, sensitive, accurate and precise for the 
quantification of SECO, ED, and EL in rat serum. The simple sample preparation and short run 
time lowers the costs associated with sample processing and allows handling a number of 
samples in a relatively short time period. Simultaneous quantification of all SDG metabolites 
makes the method suitable for a complete pharmacokinetic analysis of lignans in the rat and 
possible transfer to other matrices and species. 
 
54 
5.3 Assessment of the Pharmacokinetics (PK) of Secoisolariciresinol (SECO) 
After Single Intravenous (IV) and Oral Bolus Administration in Rat 
The third objective of my research was to assess the pharmacokinetics of SECO after a 
single intravenous and oral bolus administration in rat. Pharmacokinetic characterization of the 
compound helps identify the relationship between exposure to the compound and observed 
effect, which is critical in drug design and discovery process. To date, limited PK data exist for 
flaxseed lignans and SECO, especially, as it was assumed that only enterolignans are responsible 
for reported health benefits and SECO is a minor metabolite of SDG3. On the other hand, recent 
studies suggest that SECO is found in detectable quantities in plasma of many species, giving a 
new prospective on which lignan form elicits the observed health benefits 94,121. Taking into 
consideration that many studies on biological activity were conducted with a dietary source of 
lignans as opposed to pure compounds, little research was done regarding potential contribution 
of SECO to observed health effects. 
 
5.3.1 The 12-hour Pharmacokinetic Study 
The aim of this experiment was to study the time course of SECO concentration in the rat 
after intravascular (intravenous) and extravascular (oral) administration and determine SECO 
pharmacokinetic parameters. Two pilot studies preceeded the experiment to find the sampling 
schedule appropriate for the most accurate monitoring of SECO, as it was found to be absorbed 
very fast. Unfortunately, selected time points did not allow for simultaneous quantification of ED 
and EL. Results of pilot studies showed that ED was detected in 8 hours, while EL was detected 
in18 hours after the dose administration. Therefore, more time points were required at the 
interval between 8 and 24 hours, which was not possible without causing distress in animals due 
to excessive blood loss. For animal welfare reasons it was decided to conduct a separate 48-hour 
experiment to monitor changes in ED and EL levels. 
Large interindividual variation in SECO serum levels was observed following both routes 
of administration, which is consistent with other lignan experiments111,112,120. SECO 
concentration declined rapidly during the first hour after IV injection and by the end of 
experiment was below the LOQ of the assay in four out of six rats, while in two animals SECO 
was present in somewhat significant quantities. The lignan showed two-compartment model 
characteristics with an extensive distribution phase.  
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Following oral administration, two distinct spikes in SECO concentration were observed 
in the intervals 5-15 min and 45-60 min after the dose. A third spike was observed in three 
animals at 8 or 12 hours post dose, while another two showed a plateau between 4 and 12 hours. 
The second peak of SECO serum levels may be explained by disruption in gastric emptying 
caused by short-term isoflurane anaesthesia which was used to avoid distress in the animals 
during the oral gavage. Brief isoflurane anaesthesia was found to significantly reduce gastric 
emptying and gastrointestinal motility in rats measured by charcoal technique150. During the 
experiment, rats were gavaged with gelatin capsule filled with activated charcoal.The effect of 
anaesthesia on gastric emptying of liquids was not assessed150. It is possible that due to delayed 
gastric emptying initial absorption occurred in the stomach while a second peak was the result of 
SECO absorption from the intestine.   
Another possible explanation for the second spike in SECO serum levels is that it 
undergoes enterohepatic recirculation. Under fasted conditions gastric emptying of the liquid 
marker in rats occurs much faster than in fed state and results in early and high serum levels of 
coadministered drugs151,152. For example, an early peak plasma level was observed after an oral 
gavage of diclofenac in rats153. The study investigated diclofenac pharmacokinetics in rats, 
including enterohepatic recirculation using normal and bile duct-cannulated rats. After 
intraduodenal administration of diclofenac, plasma levels in normal animals showed a plateau 1 
hour after the dose, while in the bile-duct cannulated animals, diclofenac plasma concentration 
continued to decline153. Some anatomical differences such as constant bile flow and elevated β-
glucuronidase activity in the proximal small intestine compared to humans may also shorten time 
for lignans to be excreted into the duodenum, hydrolyzed and then reabsorbed146,154. On the other 
hand, a pharmacokinetic study with structurally similar resveratol using linked-rat model showed 
a plasma peak attributed to enterohepatic recirculation in bile-recipient rats 6 hours after the oral 
dose, which is consistent with third spike of SECO levels in my study155. The very high early 
peak of SECO is somewhat unusual for orally administered compounds. Although it is possible 
that some absorption have occurred in the stomach, the surface area of the stomach mucosa is 
much smaller in the comparison to the mucosa of the proximal small intestine146. Further 
experiments are needed to fully understand SECO absorption and disposition characteristics 
following oral administration. 
A non-compartmental approach was used to determine SECO PK parameters. Systemic 
exposure to SECO after oral bolus is much lower compared to intravenous administration 
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resulting in low oral bioavailability. SECO exhibits an extensive volume of distribution 
consistent with earlier studies on lignan disposition in the rat107,109. A relatively short half-life is 
similar to the half-lives of other plant lignans, such as pinoresinol, lariciresinol and 7-
hydroxymatairesinol in humans121. Secondary serum concentration peaks indicate the presence 
of enterohepatic recirculation also observed by Penalvo et al.121 for SECO and by Kuijsten et 
al.113 for ED and EL in humans. 
 
5.3.2 The 48-hour Pharmacokinetic Study 
An additional 48-hour study was conducted in order to monitor the ED and EL 
concentration profile. Unfortunately, I was not able to quantify enterolignans in the majority of 
the samples. ED was detected in samples starting from 8 hours after the dose administration and 
was quantified at 21-24 hour time points following IV bolus only. EL was detected in samples 
from 15 to 36 hours post dose. Unfortunately, the developed method has lower sensitivity for EL, 
which could explain why EL was not quantified. ED and EL were found to undergo extensive 
glucuronidation in human and rhesus monkey hepatocytes97. Study on enterolignan intestinal 
metabolism using human Caco-2 cells also showed that EL is more readily conjugated than ED, 
which might contribute to my inability to quantify EL in the serum samples98. The delayed 
appearance of ED and EL is consistent with the results of PK studies in humans113,120,121. I also 
attempted to evaluate conjugated lignans by incubating serum with β-glucuronidase before 
analysis; however, interfering endogenous peaks that may have arisen from rat diet precluded 
quantification of the conjugated lignans. 
Interestingly, unconjugated SECO was found in the systemic circulation up to 21 hours 
after the dose, with one animal showing significant quantities 36 hours post dose. This finding 
gives a new prospective on a possible biologically active lignan molecule. Felmlee et al.1 
observed that oral administration of equimolar quantities of SDG or SECO to Wistar rats fed 1% 
cholesterol diet caused dose-dependent reductions in serum total and LDL-cholesterol levels, 
hepatic lipid accumulation and the rate of body-weight gain. Although the exposure to 
enterolignan conjugates is reported to be much higher than to plant lignan conjugates across 
species, glucuronide formation usually serves as an elimination pathway for xenobiotics94,121,156. 
Glucuronides are polar, water-soluble, usually pharmacologically inactive compounds that are 
eliminated from the body more easily than their aglycones156. To my knowledge, no studies have 
assessed the concentration profile of unconjugated ED and EL, while my experiments indicate 
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that exposure to unconjugated SECO in rats is much higher than to unconjugated ED or EL. 
Moreover, to date no information is available on the pharmacological activity of lignan 
glucuronides as well. Therefore, the hypocholesterolemic effect in rats observed by Felmlee et 
al.1 could be attributed at least partially to SECO. Recent study on chronic exposure to rye 
lignans in pigs also indicated high levels of plant lignans in systemic circulation and especially in 
bile (up to 77%)94, warranting further experiments on lignan metabolism. 
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 6. CONCLUSIONS AND FUTURE DIRECTIONS 
The purpose of this research was to determine the pharmacokinetic parameters of SECO, 
the aglycone of the flaxseed lignan, SDG, in the rat animal model to help better understand 
lignan pharmacology. To complete the project, I needed sufficient quantity of pure SECO for the 
pharmacokinetic study, which is not readily available on the market. I also needed a simple and 
reliable method for lignan quantification in rat serum. 
For my first objective, pure SECO (≥95% purity) was produced by acid hydrolysis of 
purified SDG isolated from the starting lignan material (40% SDG) by preparative HPLC. The 
molecule identity was confirmed by quadrupole time-of-flight mass spectrometry in negative 
ionization mode. SECO purity was confirmed by UPLC analysis. 
For my second objective, an HPLC method with fluorescence detection for SECO, ED 
and EL quantification in rat serum was developed and validated. The method is rapid, provides 
good analytical sensitivity, and requires small serum volumes compared to currently available 
HPLC methods for lignan analysis. Although methods for lignan quantification involving mass 
spectrometry offer higher sensitivity, they are not available to many laboratories and often 
require radiolabeled or deuterated standards that need to be additionally synthetized. The 
developed method also allows for the simultaneous determination of all main metabolites of 
SDG, the major lignan in flax, making it suitable for complete pharmacokinetic lignan analysis 
in rat serum. 
For my third objective and overall purpose of the project, two PK studies were conducted 
in male Wistar rats following a single intravenous and oral bolus administration of SECO. 
Lignan pharmacokinetic parameters have been assessed based on the results of a 12-hour study. 
SECO exhibits two compartment model characteristics with a large volume of distribution and 
low oral bioavailability. Oral data suggest that SECO undergoes enterohepatic recirculation. The 
results of a 48-hour study indicate that SECO is present in the systemic circulation at least for 21 
hours after the dose administration. ED was detected and quantified in the samples taken 
between 8 to 24 hours, and EL was detected in samples taken between 15 to 36 hours after the 
SECO administration. Study results suggest SECO might significantly contribute to the 
cholesterol lowering effect observed in rats fed cholesterol diet following once a day oral 
administration of SDG or SECO. 
Additional pharmacokinetic studies with SDG, ED and EL are necessary to understand 
which lignan form may mediate the beneficial health effects of flaxseed. Complete analysis of 
59 
bile, urine and faeces, as well as a thorough investigation of enterohepatic circulation of lignans 
could contribute to the understanding of lignan efficacy and mechanism of action. 
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